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ABSTRACT 
Black South African women who have breast cancer have been found in general to be diagnosed at a 
younger age, have a more aggressive disease and a poorer prognosis in comparison to their 
Caucasian counterparts. However, there is a paucity of research related to the manner in which 
breast cancer is inherited in black South African families. It is also not known whether these 
individuals harbour deleterious mutations in breast cancer predisposition genes. As 5-10% of breast 
cancers have been shown to be inherited, in white populations, this study aimed to investigate family 
history and inheritance of breast cancer in black South African women. It also aimed to evaluate the 
use and consistency of existing risk assessment models in this population. 
A retrospective, file-based analysis of 45 black South African women who were diagnosed with breast 
cancer before the age of 50 years was performed. The probands were ascertained from the Genetic 
Counselling Clinic held weekly at the Breast and Plastic Clinic, Chris Hani Baragwanath Hospital. 
Information was obtained from the subjects’ genetic counselling files as well as the Oncology 
database that is housed at the Clinic. Information pertaining to the personal breast disease history of 
the probands as well as their family histories (three generation pedigrees) was entered into a 
spreadsheet and analysed.     
The results of this study indicated that there were very few young black South African women with 
breast cancer who had a significant family history of cancer (4/45; 9%). Family history is an important 
factor in assessing an individual’s breast cancer risks. Results also suggested that age at diagnosis 
may not be an appropriate predictor of inherited breast cancer risk in this population. A significant 
proportion of black South African women diagnosed with breast cancer younger than 50 years might 
be proven to have sporadic rather than inherited breast cancers.   
Three risk assessment tools (The Claus Model, the Tyrer-Cuzick Model and the Manchester Scoring 
system) were evaluated in this study. They were shown to have some degree of consistency and 
each had unique advantages and disadvantages of use within this population. The main limitation of 
these risk assessment tools is that they were designed based on data from Caucasian populations 
and as such their applicability to a non-Caucasian population has not been validated. Their true 
validity within this population can only be established once molecular genetic analysis has been 
performed.  
This study highlights the necessity of molecular genetic screening in this population in order to further 
delineate which individuals in this population are truly at an increased risk of developing inherited 
breast cancer. This information is important because it can inform which individuals would benefit 
from cancer risk assessments and various cancer prevention and reduction strategies. Information 
obtained from this study will be useful to direct future research in this population with respect to 
genetic counselling for inherited breast cancer.   
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1 INTRODUCTION 
Cancer (Latin for “crab”) is a term used to describe a group of non-communicable diseases 
characterized by the rapid production of abnormal cells. These cells can grow beyond their 
normal boundaries and invade nearby locations as well as more distant locations. Cancer 
can occur in any part of the body however the most common sites are: lung, stomach, liver, 
colon, rectum, cervix and breast (World Health Organization [WHO], 2011).  
An alternative term to describe cancer is “Neoplasia” (“new growth”). However, this term 
does not give any indication of whether or not a neoplasm (tumour) is benign or malignant. 
This is an important differentiation to make since only a malignant neoplasm has the 
potential to metastasize. Metastasis occurs when malignant tumour cells are transported to 
locations at a distance from the primary site within the body. This usually has more drastic 
implications for an individual than a benign tumour (Paterson and Cronje, 2008).  
The focus of the current research is breast cancer, with particular reference to the role of 
family history in predicting the occurrence of this form of cancer in the local black South 
African population- a historically under-researched group.  As an introduction to this topic 
this chapter will describe the literature relating to pertinent aspects of breast cancer. The 
discussion will start with a description of the most common types of breast cancer including 
the inherited forms of breast cancer. Hereditary Breast and Ovarian Cancer syndrome 
(HBOC) is the commonest inherited form of breast cancer. The two most common genes 
associated with HBOC, namely, BRCA1 and BRCA2 will also be discussed. From this 
foundation, breast cancer in the context of the developing world will be highlighted, with 
specific reference to the local black South African population. The manner in which 
individuals at risk of developing inherited breast cancer are identified will be highlighted. 
Emerging from this discussion, this chapter will conclude with a description of the research 
questions and specific objectives that were addressed in this research study.   
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1.1 Breast Cancer 
Breast cancer refers to the presence of a malignant neoplasm in the breast tissue. Benign 
tumours in the breast also occur. These are not life threatening but may predispose an 
individual to developing malignant tumours of the breast at a later stage (Ely and Vioral, 
2007). Breast cancer has traditionally been seen as a disease that mostly affects older 
women. However younger women, as well as men, develop breast cancer. 
Most breast cancer cases (90-95%) are thought to occur as a consequence of sporadic 
mutations that accumulate during the lifetime of an individual. In fact, breast cancer may be 
considered as having a multifactorial aetiology with genetic, hormonal, environmental, 
nutritional and other influences all participating in its development (Jardines, Haffty, Fisher, 
et al., 2005). An accumulation of somatic mutations eventually results in transformation of a 
normal cell into one with malignant potential. Coupled with environmental influences, breast 
cancer can develop (Haites and Gregory, 2002).  
1.1.1 Breast Cancer Classification 
Breast cancers among individuals differ in their histological, biological and immunological 
properties (Ely and Vioral, 2007). Breast neoplasms can be broadly categorized into non-
invasive and invasive types based on pathological findings. Non-invasive breast neoplasms 
include Ductal Carcinoma in situ (DCIS), which is a cancer that is confined to the ducts 
without spread to the actual breast tissue. Similarly, Lobular Carcinoma in situ (LCIS) is 
another type of non-invasive breast disease that is confined to the milk-producing glands of 
the breast. Other non-malignant breast diseases are fibroadenomas, phyllodes tumours and 
intraductal papillomas.  
The most common type of invasive breast cancer is infiltrating ductal carcinoma (IDC). IDC 
begins in a duct and is able to invade the surrounding breast tissue. It also has the potential 
to metastasize to other areas of the body. Similarly, infiltrating lobular carcinoma (ILC) 
begins in the glands and may spread to distant sites (Ely and Vioral, 2007). 
1.1.2 Receptors in Breast Cancer 
Breast cancers can also be classified according to the presence of hormonal and growth 
factor receptors on tumour cells, which can contribute to cancer prognosis, management and 
treatment. The main biomarkers that are used for breast cancer classifications are estrogen 
receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 
(HER2) (Allred, 2010).  
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Estrogen receptors are activated by estrogen and assist growth regulation and differentiation 
in normal breast cells. ER expression is predictive of response to hormonal therapies such 
as Tamoxifen® and aromatase inhibitors. Approximately 75% of invasive breast cancers 
express ER (Allred, 2010).  
Progesterone receptors are expressed after activation by progesterone and are associated 
with cell proliferation in normal and tumour cells. Although ER also regulates PR expression, 
the two are not directly correlated. PR is a predictive factor for response to hormonal 
therapy. Even tumours with low levels (≥1%) of PR-positive expression are able to respond 
significantly to hormonal therapies like the aromatase inhibitors (Allred, 2010). 
HER2 is an epidermal growth factor receptor that regulates cellular proliferation and 
apoptosis. The gene encoding the HER2 receptor is up-regulated in 15% of invasive breast 
cancers. HER2 expression contributes to chemotherapy choice. HER2-positive tumours 
react positively to novel anti-body therapies (e.g. trastuzumab or Herceptin®) which 
specifically target HER-2 proteins (Allred, 2010).   
Four main phenotypes of expression can result when the three biomarkers are evaluated 
together (ER/PR+, HER2+; ER/PR+, HER2-; ER/PR-, HER2+ and ER/PR-, HER2-).  Each of 
the phenotypes has been found to have different baseline characteristics as well as different 
responses to hormonal therapies and eventual outcomes (Onitilo, Engel, Greenlee, et al., 
2009). Tumours that are negative for the expression of all three of these receptors (also 
known as triple negative breast cancers) are commonly thought to be more difficult to treat 
since they do not respond to hormonal or antibody therapy.  
1.1.3 Breast Cancer Diagnosis, Treatment and Management 
The process from breast cancer diagnosis to treatment is a multi-step one that may begin 
with a physical examination of the breasts when cancer is suspected (O’Connell and Dickey, 
2005). Baseline assessments to assess a potential breast cancer diagnosis include a 
mammogram, ultrasound, fine needle aspiration (FNA) and core biopsy. Once a diagnosis of 
breast cancer has been confirmed, additional tests may be requested (e.g. liver and bone 
studies, full blood counts, CT scans and hormone receptor studies) in order to more fully 
evaluate the cancer and determine whether metastasis has occurred (O’Connell and Dickey, 
2005).  
These procedures all contribute to the classification and staging of a tumour. These can be 
assigned based on the American Joint Committee on Cancer’s (AJCC) Tumour, Nodes, 
Metastases (TNM) staging for breast cancer. Staging is important as it gives an indication of 
prognosis. TNM staging is evaluated clinically and then reiterated and adjusted after 
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histopathological analysis and surgical findings. A number is assigned for each of three 
categories, namely: the size and extent of local penetration of a Tumour, the number of 
cancerous lymph Nodes, and the presence or absence of distant Metastasis (spread). 
Following staging, a tumour will be assigned a grade (from I to IV). This grade is reflective of 
how advanced the cancer is (in other words, the higher the number the more advanced the 
cancer). The assignment of a tumour to a stage and grade is complex. A comprehensive 
explanation can be found at http://www.cancerstaging.org.   
Surgery and treatment decisions are made in conjunction with a patient’s wishes based on a 
review of imaging studies, clinical examinations as well as FNA, biopsy and histopathological 
results (Hammer, Fanning and Crowe, 2008). Surgery is an essential component in the 
treatment plan of almost all individuals who have been diagnosed with breast cancer. 
Surgical protocol also dictates an assessment of the regional lymph nodes for metastasis 
(Hammer et al, 2008). 
Breast conservation therapy (also referred to as “partial mastectomy”, “segmental 
mastectomy”, “quadrantectomy” or “lumpectomy”), is the process whereby the cancerous 
area, as well as the immediate normal tissue surrounding it, is removed. The aim of such a 
technique is to achieve a normal appearance of the breast after surgery. This procedure is 
generally followed by a course of radiation therapy to treat the remaining breast tissue. This 
procedure is not always possible especially in the case of multicentric or large tumours 
(Hammer et al, 2008). 
A modified radical mastectomy involves removal of the entire breast as well as indicated 
lymph nodes but is performed in order to conserve the muscles surrounding the breast. A 
simple (or “total”) mastectomy also removes the breast but leaves lymph nodes intact. 
Improved aesthetic results can be achieved through the use of skin-sparing mastectomies 
and nipple-areola-sparing mastectomies (Hammer et al, 2008).     
Adjuvant chemotherapy is included when necessary and chemoprevention medication such 
as Tamoxifen® is added if receptor studies indicate that this may be useful (O’Connell and 
Dickey, 2005). Reconstruction surgery options are varied and also depend on the 
requirements of the patient.   
1.1.4 Risk Factors for Breast Cancer 
It is important to understand the factors that contribute to an individual’s risk for breast 
cancer since this leads to appropriate counselling, treatment and management. Further, it is 
necessary to consider that causative and protective factors interact in a complex manner in 
order for breast cancer to develop.  
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The most important risk factors in breast cancer are increasing age and female gender 
(Steiner, Klubert and Knutson, 2008). Non-modifiable risks include reproductive factors as 
well as genetic mutations and family history. Other modifiable factors that affect an 
individual’s risk of developing breast cancer include diet, behaviour and lifestyle (Steiner et 
al, 2008). Major factors that alter an individual’s risk for breast cancer are outlined in Figure 
1-1. 
    
 
 
 
 
 
  
 
 
 
 
 
Family history is the most significant risk factor in breast cancer since collectively it may 
indicate the presence of a mutation in a breast cancer predisposing gene (discussed in detail 
in section 1.3.1). In this case the risk of developing breast cancer (and other associated 
cancers such as ovarian cancer) may be significantly increased.  
  
Figure 1-1 Independent factors that modify an individual's risk for breast 
cancer. Factors on the left indicate those that increase breast cancer risk while 
those on the right indicate those that decrease breast cancer risk (Adapted from 
Steiner et al., 2008). 
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1.2 Breast Cancer Incidence and Epidemiology 
According to the WHO, breast cancer is responsible for ±380 000 female deaths per year 
worldwide. The incidence of breast cancer is rising throughout the world, with breast cancer 
steadily approaching similar figures to cervical cancer – the commonest cause of female 
cancer deaths in the developing world (WHO, 2010). Significant variation in breast cancer 
incidence does exist in different parts of the world (Akaralo-Anthony, Ogundiran, and 
Adebamowo, 2010). In the United Kingdom, the risk for developing breast cancer in a 
woman’s lifetime is 1 in 10 (Kerr, Lalloo, Clancy et al., 2010).  
The most recent South African statistics show that the minimum lifetime risks of developing 
breast cancer for Caucasian women are 1 in 11, 1 in 18 for women of mixed ancestry and 1 
in 55 for African women (Mqoqi, Kellett, Sitas, et al., 2004; National Cancer Registry, 2009). 
These lifetime risks are known to be underestimates as a consequence of the fact that data 
are collected through a passive pathology-based surveillance system and many 
malignancies go unreported. In addition, if information obtained about a particular individual 
is incomplete, the related data are disregarded. Delays in publishing reports on South 
African cancer statistics have been attributed to difficulties in receiving data from private 
pathology laboratories (National Cancer Registry, 2010).  
1.2.1 Changing Breast Cancer Epidemiology in Africa 
Global incidence of breast cancer is rising steadily (Akaralo-Anthony, et al., 2010). Breast 
cancer incidence is relatively lower in developing populations such as Asia and sub-Saharan 
Africa. However, as urbanisation becomes increasingly prevalent, the incidence of breast 
cancer in these populations is rising (Walker, Adam and Walker, 2004). In large part, this 
can be attributed to an increased life expectancy due to changes in diet and reproductive 
patterns. Nutritional changes and decreased physical activity have contributed to the age at 
onset of menarche decreasing. In addition, better access to education as well as improved 
lifestyle choices has caused a delay in the age of first pregnancy. This delay has further 
prompted a decreased rate of fertility which in turn has lead to reduced lifetime breast 
feeding duration (Akaralo-Anthony, et al., 2010). These changes are thought to influence an 
altered pattern of breast cancer incidence.  
In the past, this change in the epidemiological trend has constantly been eclipsed by the lack 
of control over infectious diseases in developing populations. More recently however, there 
has been an increase in attention given to the epidemic of breast cancer as its effects 
become more and more apparent in developing countries, of which South Africa is a prime 
example (Akaralo-Anthony, et al., 2010). 
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The black South African population appear to be following similar trends of breast cancer 
incidence. Although incidence of breast cancer in this population is lower than Caucasian 
and African-American populations, it is increasing.  
Other breast cancer trends in African women include a younger age and later stage 
presentation at diagnosis (Walker, et al., 2004). Stark, Kleer and Martin, et al., (2010) 
indicate that these factors contribute to the rate of mortality in this population being 
paradoxically higher than the incidence rate.    
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1.3 Familial / Inherited Breast Cancer 
Although, post-menopausal women are more likely to develop breast cancer, there are an 
increasing number of women under the age of 50 years who are developing breast cancer. 
In the United States, 2.7% of women affected with breast cancer are younger than 35 years 
old (Shannon and Smith, 2003). In Algeria, 55% of women affected with breast cancer are 
younger than 50 years old (Uhrhammer, Abdelouahab, Lafarge et al., 2008). Younger 
women affected with breast cancer are more likely to have an inherited/familial form of 
breast cancer (Fackenthal, Sveen, Gao, et al., 2005).  
Approximately 5-10% of all breast cancers are attributable to an inherited susceptibility 
(Wood, 2010). An inherited susceptibility to breast cancer is suspected under one or more of 
the following circumstances (Jardines, et al., 2005): 
 Young age at diagnosis 
 Multiple cases of close relatives with early-onset breast cancer 
 Ovarian cancer (within the context of a breast and ovarian cancer family history) 
 An individual with both breast and ovarian cancer (irrespective of age) 
 Bilateral breast cancer 
 Male breast cancer 
 Ancestry from a high risk population (e.g. Ashkenazi Jewish population) 
1.3.1 Cancer Genes  
Cell division is a highly regulated process dependent on transcription and translation of 
genes. If this process malfunctions or is non-functional, cellular growth becomes 
disregulated and may result in cancer formation. It has been found that some genes 
controlling cell division are mutated in neoplastic tumours. These genes are categorised into 
three groups based on their normal functions. They are: proto-oncogenes, tumour 
suppressor genes and mismatch repair genes. Oncogenes and tumour suppressor genes 
function together to ensure normal regulation of cell division (Paterson and Cronje, 2008).  
Proto-oncogenes (e.g. the Ras or myc genes) produce proteins that stimulate cell 
proliferation when prompted by internal and external cellular signals (Whalley and 
Hammond, 2008). Only a single copy of a proto-oncogene needs to mutate for the gene to 
cause unregulated cell division. Therefore conditions involving mutations in proto-oncogenes 
are said to be dominantly inherited.   
Tumour suppressor genes (TSG) play a fundamental role in regulation of transcription and 
inhibition of cellular growth (Hammond, 2008). Tumour suppressor genes are recessive at 
the cellular level and require both copies of the gene to be mutated to render a protein 
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product non-functional. At a phenotypic level, tumour suppressor genes are inherited in a 
dominant pattern. Tumour suppressor genes include Breast Cancer Gene 1 (BRCA1), 
Breast Cancer Gene 2 (BRCA2), p53 gene and Retinoblastoma gene (Rb) (Hammond, 
2008).    
DNA Mismatch Repair (MMR) is the mechanism by which erroneously incorporated or 
deleted bases during DNA synthesis are corrected. In Hereditary Non-Polyposis Colorectal 
Cancer (HNPCC) or Lynch Syndrome, MLH1, MSH2, and MSH6 mismatch repair genes 
have been found to be defective (Capovilla, 2008). 
If an inherited susceptibility exists in a family history with breast and/or ovarian cancer, it is 
most commonly linked to mutations in cancer predisposing genes like BRCA1 or BRCA2. 
Germline mutations of BRCA1 and BRCA2 can be heritable. BRCA1 and BRCA2 mutations 
account for a large proportion of inherited breast and/or ovarian cancer cases in 
European/Caucasian populations (Morrison, Hodgson and Haites, 2002).  
Germline mutations in BRCA1 and BRCA2 do not however, account for all cases of familial 
breast cancer. Accordingly, low penetrance susceptibility genes that play a role in the 
aetiology of inherited breast cancer have also been identified. The commonality between 
high (BRCA1, BRCA2, p53 and pTEN) and low (e.g. PALB2, CHEK2 and ATM) penetrance 
breast cancer susceptibility genes is that they all function in DNA damage response 
pathways (Venkitaraman, 2004).  
Mutations in the p53 and pTEN genes have been found to confer high risks of breast cancer 
in association with the rare genetic conditions, Li Fraumeni Syndrome and Cowden 
Syndrome respectively (Walsh and King, 2007). Fanconi Anaemia, an autosomal recessive 
condition that has a high risk of cancer susceptibility, can be caused by biallelic mutations in 
BRCA2, PALB2 and BRIP1. Further, heterozygous mutations in PALB2, CHEK2, ATM and 
others also confer increased breast cancer risks (approximately double) in the context of 
inherited breast cancer. With consideration of all relevant loci and alleles, it is reasonable to 
conclude that inherited breast cancer is a highly genetically heterogeneous condition (Walsh 
and King, 2007).  
These breast cancer genes have also been found to confer increased risks for other cancers 
when mutated. Details of these cancers as well as other aspects of the genes are listed in 
table 1-1. Even in the absence of identifying a disease causing mutation, there is clear 
benefit from being identified as high risk for developing breast cancer and these individuals 
should be offered regular surveillance (Morrison et al., 2002).  
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Table 1-1 Features of some genes associated with breast cancer susceptibility (Online 
Mendelian Inheritance in Man [OMIM], 2011) 
Feature: P53: PTEN: PALB2: CHEK2: ATM: BRIP1: 
Chromosomal 
Location: 
17p13.1 10q23.31 16p12.2 22q12.1 11q22.3 17q23.2 
Protein 
Function: 
Responds to 
cellular stress 
Organization 
of different 
cell types 
during 
development 
Co-localizes 
with BRCA2 for 
recombinational 
repair and 
checkpoint 
functioning 
Cell cycle 
arrest in 
response to 
DNA damage 
DNA 
damage 
response 
Double-
stranded 
break 
repair 
Higher 
Incidence of 
Other 
Cancers: 
Adrenocortical; 
colorectal; 
osteosarcoma; 
pancreatic 
Thyroid; 
endometrial; 
skin 
Oesophagus; 
prostate; 
stomach; 
pancreas 
Osteosarcoma; 
colorectal; 
prostate 
Kidney Ovarian 
 
1.3.2 Hereditary Breast and Ovarian Cancer Syndrome 
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is the genetic condition 
associated with the inheritance of mutations in BRCA1 and BRCA2 genes. This type of 
inherited breast cancer arises when one BRCA allele is inherited in a mutated form and the 
second BRCA allele is somatically mutated in the breast tissue (Welsch and King, 2001).   
HBOC follows an autosomal dominant pattern of inheritance within families. In other words, 
a mutation is required in only a single copy of a gene in order for there to be a risk of 
developing the disease. In addition, the risk of passing on a mutated BRCA allele to a 
subsequent generation is 50%.  Identification of a BRCA1 or BRCA2 mutation provides a 
conclusive diagnosis of HBOC in a family. Identifying mutations in BRCA1 and BRCA2 has 
vast implications for at-risk family members. BRCA mutation status has bearing on the 
surveillance, treatment and management of breast and/or ovarian cancer (Petrucelli, Daly 
and Feldman, 1998).  
1.3.3 BRCA1 and BRCA2 Genes 
Miki, Swensen, Shattuck-Eidens, and colleagues (1994) identified BRCA1 as the first 
susceptibility gene associated with Hereditary Breast and Ovarian Cancer Syndrome 
(HBOC) in 1990. The gene had been successfully cloned in 1994 (Miki, et al., 1994). Soon 
after, BRCA2 was identified and cloned (Wooster, Bignell, Lancaster et al., 1995). Since 
then, BRCA1 and BRCA2 genes have been found to be mutated in both sporadic and 
familial breast cancers. Mutations in BRCA1 and BRCA2 lead to chromosomal instability. 
Table 1-2 summarises the features of BRCA1 and BRCA2 genes as they relate to HBOC.  
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Table 1-2 Comparison of the features of BRCA1 and BRCA2, the two main genes 
associated with HBOC (adapted from Haites and Gregory, 2002). 
Feature: BRCA1: BRCA2: 
Chromosomal Location: 17q21 13q12-13 
Coding nucleotides 5592 11 385 
Exons 22 27 
Amino Acids in Protein 1863 3418 
Protein Function: 
Cell Cycle Control and DNA 
damage repair pathways 
Binding of RAD51 
Higher Incidence of Other 
Cancers: 
Ovarian; Colon; Prostate 
Stomach; Pancreas; 
Gallbladder; Melanoma; 
Prostate 
  
Rijnsburger, Obdejin and Kaas, et al., (2010), have further delineated the features of BRCA1 
and BRCA2 mutation carriers. Their study revealed that in comparison with BRCA2 mutation 
carriers, BRCA1 mutation carriers are: 
 Less likely to have tumours detected by mammography. 
 More likely to be negative for expression of oestrogen, progesterone and Her2/neu 
receptors  
 Less likely to be histologically lobular carcinomas 
 More likely to develop interval cancers (i.e.: cancers detected between two screening 
sessions). 
 Less likely to develop DCIS. 
 More likely to have an unfavourable tumour size (>2cm) at the time of diagnosis. 
These differences in behaviour necessitate treatment and management programmes that 
are tailored more specifically according to whether a tumour is BRCA1- or BRCA2- 
associated (Rijnsburger, et al., 2010).  
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1.4 Evidence for Inherited Breast Cancer in African Populations 
Akaralo-Anthony et al., (2010) state that high fertility rates coupled with high mortality rates 
have resulted in the African population having a low median age. As a consequence, early 
onset breast cancers account for a significant proportion of cases seen at breast cancer 
clinics throughout the continent. They argue therefore, that the early age of onset of breast 
cancer prevalent in this population is merely due to the low median age and is not 
necessarily indicative of an inherent genetic basis for breast cancer in this population 
(Akaralo-Anthony, et al., 2010).  
Counter to this argument, the phenotype of breast cancer in African women is consistent 
with the breast cancer burden that is seen in patients who have a known hereditary 
susceptibility, especially to BRCA1 mutations. Since these characteristics (as outlined in 
Section 1.3) seem to mirror those for hereditary susceptibility to breast cancer, it would seem 
feasible that a significant family history of breast cancer may also characterize the breast 
cancer burden in African individuals (Stark et al., 2010). The occurrence of a significant 
family history in a lower risk population is therefore less likely to be a chance association. 
Considering this, it seems apt to suggest that 5-10% of breast cancer cases can be ascribed 
to an inherited susceptibility in this population irrespective of the different cancer burden and 
risk profile. 
There are few genetic studies regarding BRCA mutations in the African population. 
Identification of African women at high risk of developing breast cancer could lead to further 
investigations into germline mutations associated with familial/inherited breast cancer. In 
addition, there may even be potential scope for improved treatment options especially for 
triple negative breast cancer in African women (Stark, et al., 2010). 
1.4.1 Nigerian Studies 
In order to determine the frequency and spectrum of BRCA1 and BRCA2 mutations in a 
Nigerian cohort, Fackenthal et al., (2005) peformed mutational analysis on 39 Nigerian 
women with a breast cancer diagnosis under the age of 40 years and 74 controls. Patients 
were ascertained for analysis from consecutive cases of newly diagnosed breast cancers 
unselected for age or family history. The results revealed a large amount of mutational 
variation in BRCA1 and BRCA2 however there was no evidence for a candidate founder 
mutation. Of the 39 patients, 29 had at least one variation in either or both of the BRCA 
genes. A total of 34 variants were identified, 4 in BRCA1 and 30 in BRCA2. These results 
were indicative of a role for BRCA1 and BRCA2 in breast cancer risk in this population 
(Fackenthal, et al., 2005).  
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Following this, complete BRCA1 and BRCA2 sequencing was performed on 434 Nigerian 
women with breast cancer (Fackenthal, Zhang, Zhang, et al., 2011). Sixteen BRCA1 
mutations (7.1%) were identified in the cohort, 7 of which were novel. In addition, 13 BRCA2 
mutations (3.9%) were identified, 6 of which had not been previously reported. In these 
patients, mutations were found to be more prevalent in those with family histories of breast 
cancer as well as those diagnosed with breast cancer at a younger age (Fackenthal, et al., 
2011).    
1.4.2 African-American Studies 
In a review of breast cancer genetics in African Americans by Olopade, Fackenthal, 
Dunston, et al., (2003), 26 distinct BRCA1 and 18 distinct BRCA2 pathogenic mutations 
have been identified in this population. This spectrum of mutations is thought to be unique to 
this population. In addition, 23% of pathogenic BRCA1 mutations and 17% of pathogenic 
BRCA2 mutations were detected in more than one family of African or African-American 
descent (Olopade, et al., 2003).   
Traits that characterize breast cancer in African-American women include diagnosis at a 
younger age, diagnosis of high grade triple negative receptor tumours (Stark et al., 2010) as 
well as higher incidences of male breast cancer (O’Malley, Shema, White, et al., 2005). The 
triple negative receptor phenotype (as well as other characteristics) in African-American 
women diagnosed with breast cancer has been validated by similar findings in indigenous 
African populations from Ghana (Stark et al., 2010), Kenya (Bird, Hill and Houssami, 2008) 
and Nigeria and Senegal (Huo, Ikpatt, Khramstov, et al., 2009). 
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1.5 HBOC in South Africa 
HBOC in South Africa is unique from a genetic perspective. Two well-known founder 
populations, namely, the Afrikaans and Ashkenazi Jewish populations have been intensively 
researched regarding their predispositions to genetic disease. For example, each of these 
populations has been found to have common founder mutations in BRCA1 and BRCA2 
genes (Table 1-3) (Struewing, Hartge, Wacholder, et al., 1997; Reeves, Yawitch, van der 
Merwe, et al., 2004).  
Table 1-3 Common BRCA gene founder mutations in the Afrikaner and Ashkenazi Jewish 
populations 
Population: 
Common BRCA1 founder 
mutations 
Common BRCA2 founder 
mutations 
Afrikaans 
c.1374delC;  
c.2641G>T 
c.7934delG 
Ashkenazi Jewish 
c.68_69delAG; 
c.5266_5267insC 
c.5946delT 
 
A third population, namely, the black South African population is not frequently thought of as 
a founder population considering the general propensity of African populations towards 
increased genetic diversity (Olopade, et al., 2003). Despite this, founder mutations have 
been identified in the black population. Examples include founder mutations in the FANCG 
gene resulting in Fanconi Anaemia (Morgan, Essop, Demuth, et al., 2005) as well as in the 
HDL2 gene resulting in Huntington’s Disease (Magazi, Krause, Bonev, et al., 2008). 
Research has not yet been done to ascertain whether or not founder mutations exist in the 
Black South African population for HBOC. It is known however that the common mutations 
found frequently in the Afrikaans and Ashkenazi Jewish populations and in African-American 
populations (e.g. 943ins10 in BRCA1) have not been detected in black South African women 
who have breast cancer (Neuhausen, 2000, Yawitch, van Rensburg, Mertz, et al., 2000).  
Recently, it has been proposed that a “founder” BRCA2 mutation exists in a group of breast 
cancer patients specific to the Western Cape region of South Africa.  A c.5771_5774del 
(p.Ile1924ArgfsX38) mutation in the BRCA2 gene was found in individuals from both the 
mixed ancestry as well as Xhosa populations from this area. Gene flow is postulated to have 
occurred from the indigenous Xhosa population to the mixed ancestry population, evidenced 
by the common haplotype between them (van der Merwe, Hamel, Schneider, et al., 2011). 
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1.6 Breast Cancer Cohort Profile 
The Breast and Plastic Clinic located at the Chris Hani Baragwanath Hospital (CHB) in 
Southern Johannesburg is an academic surgical teaching unit dedicated to the diagnosis 
and treatment of both benign and malignant breast conditions (SenoNetwork, 2010). The 
clinic falls under the directorship of Dr Herbert Cubasch (FCS SA). The Hospital serves a 
population of 2.5 million from Soweto and the surrounding areas.  The out-patient clinic, 
which runs every Wednesday, is responsible for diagnosis of breast cancer cases while 
adjuvant chemo- and radio- therapy is performed at the Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH). Both hospitals are associated with the University of the 
Witwatersrand (WITS). The Breast and Plastic Clinic is recognised as a multidisciplinary 
breast centre by SenoNetwork, an international network of breast cancer centres under the 
joint guidance of the European Society of Breast Cancer Specialists (EUSOMA) and the 
European School of Oncology (ESO) (SenoNetwork, 2010).  
1.7 Breast Cancer Genetic Counselling Services 
Genetic counselling services are available to those individuals at the Breast and Plastic 
Clinic, CHB who appear to be at an increased risk of developing breast cancer based on 
their family histories as well as other pertinent information (e.g. age at diagnosis or receptor 
status).  Genetic Counselling is provided based on the tenets set out in the definition below: 
“Genetic counseling is the process of helping people understand and adapt 
to the medical, psychological and familial implications of genetic 
contributions to disease. This process integrates the following:  
1) Interpretation of family and medical histories to assess the chance of 
disease occurrence or recurrence  
2) Education about inheritance, testing, management, prevention, 
resources, and research  
3) Counseling to promote informed choices and adaptation to the risk or 
condition”  
(Resta, Biesecker, Bennett, et al., 2006). 
A particular aim of breast cancer genetic counselling is to provide accurate and relevant 
information regarding a patient’s genetic risk factors in a supportive and educational manner.  
In order to guide treatment and management options for individuals with breast cancer as 
well as surveillance and prophylaxis options for those family members who are at elevated 
risk, risk assessment is essential. Risk assessment can also provide information regarding 
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whether or not patients require genetic testing (Wood, 2010).  Further, risk assessment may 
benefit at-risk relatives of a proband seeking genetic counselling and testing (Hampel, 
Sweet, Westman, et al., 2003). Figure 1-2 depicts the manner in which risk assessment is 
used in the genetic counselling process for breast cancer.  
 
 
 
 
 
 
  
Figure 1-2 Process of risk assessment in the context of genetic counselling for 
Inherited Breast Cancer syndromes 
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1.8 Breast Cancer Risk Assessment 
Risk assessment can be calculated for a family based on their collective history of breast 
cancer. Alternatively, risk assessment can be calculated for an individual based on her/his 
personal and family history of cancer. This categorisation is useful in indicating the level of 
screening and surveillance that would be prudent for that grouping to follow (Section 2.2.4.1 
and Table 2-2). In other words, those families found to be at average risk would not require 
increased surveillance; screening recommendations for the general population would apply. 
An increased risk for cancer would be conferred on those families found to be at moderate 
risk; these families would require increased cancer surveillance. In high risk families, the 
family history would be indicative of an inherited cancer syndrome; these families would 
benefit from increased cancer surveillance as well as genetic follow-up (Hampel, et al., 
2003).   
1.8.1 Baseline Risk Assessment 
The risk of having an inherited cancer syndrome in a family is initially assessed based on a 
review of the family history. Families can be stratified into average, moderate or high risk of 
having an inherited cancer syndrome.  
Baseline risk based on family history incorporates: 
 The proband’s own risk for cancer (e.g. age and gender).   
 The number of people in the family and the proportion of those people who are 
affected with breast cancer.  
 The degree of relationship, the ethnic background and the type of cancer of affected 
family members (Lalloo, Kerr, Friedman, et al., 2005). 
In families where an inherited cancer risk exists, a clear autosomal dominant pattern of 
inheritance may be observed. However, penetrance and expressivity of a gene may modify 
this pattern. Ethnicity (e.g. Ashkenazi Jewish, Finnish, Afrikaans populations) is a particularly 
relevant factor to take into consideration since in the absence of a significant family history it 
may still indicate a high-risk family (Lalloo et al., 2005).  
1.8.2 Risk Assessment Tools 
There are numerous risk assessment models that have been developed in order to assess 
an individual’s risk of developing breast cancer. Commonly used models are: the Gail model, 
the Tyrer-Cuzick Model, the BRCAPRO model, the Manchester Scoring Model, the Claus 
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Model and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm (BOADICEA) model.  
These models have been developed for use by individuals from all population groups. The 
data used to develop these models however, are taken predominantly from women of 
Caucasian descent. They therefore may not be as valid for women of other ethnic groups. 
Each of the models calculates risk based on different combinations of breast cancer risk 
factors.  
1.8.3 Lifetime vs. Mutation Risks 
Breast cancer risk is assessed in one of two ways. Some models assess the likelihood of an 
individual developing breast cancer in that individual’s lifetime (e.g. Gail Model, Claus 
Model). Alternatively, they assess the likelihood that an individual carries a mutation in a 
high-risk gene such as BRCA1 and BRCA2 (e.g. Manchester scoring system, BRCAPRO). 
Some models of breast cancer risk (e.g. Tyrer-Cuzick Model, BOADICEA) are able to 
assess both of these factors simultaneously (Evans and Howell, 2007).  
Various evaluations of risk assessment models have shown that no particular model is able 
to provide the best risk estimates under all circumstances (Amir, Freedman, Seruga, et al., 
2010). In addition, all models are limited in a number of ways; the ability to factor in adoption 
and family size being two common limitations. Analyses have shown that the Gail, Claus and 
BRCAPRO models all under-estimate risk especially when a proband only has a single 
affected FDR. The BRCAPRO and Tyrer-Cuzick models are both superior in estimating risk 
based on a family history of ovarian cancer. The Claus model has repeatedly been shown to 
under-estimate risk; however, its ease-of-use makes it an obvious and common choice. 
Overall, the Tyrer-Cuzick and BOADICEA models seem to perform the best and most 
accurately. Ultimately, risk model performance is highly dependent on circumstance (Amir, et 
al., 2010). 
The advantages and limitations of each of these programmes are an important consideration 
to keep in mind when performing risk assessments. The selection of a particular risk 
assessment tool over another often needs to be made on a case by case evaluation. Based 
on the relative pros and cons of each of these models as well as their ease of access and 
usability, the Claus Model, the Manchester Scoring System and the Tyrer-Cuzick Model 
were selected for use in this study. Table 1-4 summarises the risk factors that are taken into 
consideration by each of these three models of risk assessment. 
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Table 1-4 Known risk factors that have been incorporated into risk assessment models, 
which may increase or decrease breast cancer risk (adapted from Evans and Howell, 2007; 
Evans. Lalloo, Cramer, et al., 2009) 
Risk Factor 
Claus 
Model 
Tyrer-Cuzick 
Model 
Manchester 
Model 
Personal 
Information 
Age Yes Yes No 
Body Mass Index No Yes No 
Ethnicity No AJ* only No 
Hormonal / 
Reproductive 
Factors 
Age at Menarche No Yes No 
Age at First Live Birth No Yes No 
Age at Menopause No Yes No 
Use of Hormone Replacement 
Therapy 
No Yes No 
Use of Oral Contraception No No No 
Breast Feeding No No No 
Personal 
Breast 
Disease 
Breast Biopsies No Yes No 
Atypical Ductal Hyperplasia No Yes No 
Lobular Carcinoma In Situ No Yes Yes 
Ductal Carcinoma In Situ No No Yes 
Breast density No No No 
Breast 
Pathology 
Human Epidermal Growth 
Factor Receptor Status (HER2) 
No No Yes 
Estrogen Receptor Status No No Yes 
Progesterone Receptor Status No No Yes 
Family 
History 
First Degree Relative Yes Yes Yes 
Second Degree Relative Yes Yes Yes 
Third Degree Relative No No Yes 
Age of Onset of Breast Cancer Yes Yes Yes 
Bilateral Breast Cancer No Yes No 
Male Breast Cancer No No Yes 
Ovarian Cancer No Yes Yes 
Pancreatic Cancer No No Yes 
Prostate Cancer No No Yes 
*AJ – Ashkenazi Jewish 
1.8.3.1 The Claus Model 
The Claus Model is an epidemiological model of breast cancer risk assessment (Claus, 
Risch and Thompson, 1994). The model is used to calculate the lifetime risk of inheriting 
breast cancer. It relies on a set of tables that predict the occurrence of breast cancer at 
different ages depending on the occurrence of breast cancer in first- and second- degree 
relatives and their ages of onset of cancer. 
Although the tables are simple to use they are limited in that there are a number of scenarios 
that they cannot accommodate. The Claus Tables are not suitable for use with women who 
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have more than three affected relatives (Claus, et al., 1994). Further, the Claus model does 
not take into consideration any non-familial breast cancer risk factors (Rubinstein, O’Neill, 
Pieters, et al., 2002).  Considering the Claus tables were designed to reflect the risks for 
breast cancer in the 1980’s in the USA, it is necessary to adjust the resultant lifetime risk 
predictions in order to reflect current incidence rates (Evans and Howell, 2007). 
1.8.3.2 The Tyrer-Cuzick Model 
The Tyrer-Cuzick Model calculates a risk for both outputs of risk assessment (i.e.: lifetime 
and mutation risks) (Evans and Howell, 2007). This computer model evaluates risk more 
comprehensively based on extensive family history, endogenous estrogen exposure and 
benign breast disease (Evans and Howell, 2007). There are three outputs of the model: 
 10-year risk prediction 
 Beyond 10-year risk prediction (i.e.: lifetime risk prediction) 
 Mutation risk output (Boughey, Hartmann, Anderson, et al., 2010). 
The key advantage of the Tyrer-Cuzick model is that it incorporates multiple genes with 
varying degrees of penetrance (Evans and Howell, 2007). The Tyrer-Cuzick model has 
however been found to over-estimate the risk of breast cancer especially in women who 
have benign breast disease (Boughey, et al., 2010).  
1.8.3.3 The Manchester Model 
The Manchester scoring system estimates the risk of harbouring a mutation in one of the two 
main predisposing breast cancer genes (BRCA1 and BRCA2) (Evans, Eccles, Rahman, et 
al., 2004). A score is assigned for each cancer on the same side of the family (i.e.: in a direct 
blood line). The scoring system also includes the presence of ovarian, pancreatic and 
prostate cancers in a family history (Antoniou, Hardy, Walker, et al., 2008). A combined 
score of 16 points is used as a 10% threshold and a combined score of ≥ 20 corresponds to 
a 20% threshold (Evans, et al., 2004; Evans et al., 2009). Thresholds have been 
implemented as cut-offs for testing based on cost-benefit analyses since genetic testing of 
BRCA1 and BRCA2 is a costly exercise. The Manchester scoring system has higher 
sensitivity but lower specificity in comparison with other models when 10% and 20% 
thresholds are utilised (Antoniou, et al., 2008).  
1.8.4 Applicability of Risk Assessment Tools in Non-Caucasian Populations 
Considering risk assessment models have been designed and implemented based on data 
predominantly from Caucasian populations, it is reasonable to question their accuracy in a 
non-Caucasian population. Bondy and Newman (2003) reviewed the usefulness of the Gail 
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and Claus models in African-American women. The Gail model proved to be particularly 
limited in its generalizability to the African-American population.  
The Claus model calculates risk based on the number and ages of first degree relatives with 
breast cancer. It would therefore seem that this approach would be less likely to have ethnic 
disparities given that family history data are considered a reliable breast cancer risk factor. In 
accordance with this, McTiernan, Kuniyuki and Yasui et al., (2001) showed that the Gail 
model gave a lower average lifetime risk (6.1%) in an African-American population than the 
Claus Model (10.3%). The Gail model and the modified Gail model have since been shown 
to significantly underestimate the lifetime risk of developing breast cancer in African-
American women (Adams-Cambell, Makambi, Palmer et al., 2007). In a Caucasian 
population the average lifetime risk as calculated according to the Gail model was 13.2% 
compared to 11.2% according to the Claus model. Despite this, reliable evaluation was not 
possible due to small sample sizes in the African-American population and the associated 
lack of statistical power (Bondy and Newman, 2003).  
Bondy and Newman (2003) describe significant differences among individual breast cancer 
risk factors between African-American and Caucasian women. These authors concluded that 
it is likely that risk assessment models would require significant modification in order to be 
applicable to an ethnically diverse patient group.  
Currently, there are no data that give any indication of the performance of these models in 
the local South African population. In addition, no research has been done to assess the use 
of the Tyrer-Cuzick model and the Manchester Scoring System in other population groups.  
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1.9 Research Motivation and Questions 
Little has been documented about family history and inheritance of breast cancer within 
black South African families despite the increasing incidence of the condition in this 
population (Walker, et al., 2004). It would therefore be useful to examine whether or not 
there are significant family histories in black South African women who have breast cancer. 
Through this, it may be possible to determine which individuals are likely to be at an 
increased risk of developing familial breast cancer. These at-risk individuals may then be 
able to participate in cancer risk assessments and various cancer prevention or reduction 
strategies. This study was therefore designed and implemented in order to answer the 
following questions: 
 Do black South African women who have been diagnosed with breast cancer have 
significant family histories of breast cancer? 
 How do existing risk assessment models perform in black South African women who 
have been diagnosed with breast cancer? 
In order to answer these questions, black South African women who had been diagnosed 
with breast cancer at a younger age or who had a known family history of breast cancer will 
be assessed. This information was used to ascertain which individuals in this population 
could be considered at increased risk of developing breast cancer via the use of existing 
breast cancer risk assessment models and programmes. In addition, the information 
obtained may be useful to direct future studies which would aim to examine whether or not 
mutations exist in the BRCA (and other) genes of these individuals and ultimately assess 
which risk assessment tool is the most accurate for black South African women. The results 
obtained in this study might also contribute to the development of a new risk assessment 
tool to better serve the needs of this population. 
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1.9.1 Aims and Objectives 
In order to achieve the above-mentioned aims, the following specific objectives were 
proposed: 
1. To obtain the family histories and personal breast disease histories from black South 
African women who were:  
a. Diagnosed with breast cancer under the age of 50 years. 
b. Diagnosed with breast cancer at any age AND who have a known family 
history of breast and/or ovarian cancer. 
2. To use the information gathered from these individuals to delineate the breast 
disease profile of breast cancer in black South African women. 
3. To use the information gathered from these individuals to determine the number of 
first-, second- and third- degree relatives of affected women who are at increased 
risk of developing breast cancer.  
4. To use the information gathered from these individuals to calculate the risks for these 
women / their offspring / other family members developing cancer in their lifetime or 
of having a predisposing breast cancer gene mutation using three different risk 
assessment programmes. 
5. To compare the consistency of these risk assessment programmes in black South 
African women. 
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2 SUBJECTS AND METHODS 
The study was descriptive, retrospective and file-based and the analysis was quantitative in 
nature. Ethics approval was obtained from the Human Research Ethics Committee 
(Medical), Faculty of Health Sciences, the University of the Witwatersrand, reference 
number: M10961 (Appendix 1).  
This chapter will provide a description of the subjects that were selected to participate in the 
study as well as the manner in which they were recruited. The chapter will also detail the 
methods that were employed in order to obtain subject data. Finally, the chapter describes 
analysis of data.  
2.1 Subjects: 
The population under investigation in this study was black South African women. The 
subjects were ascertained through convenience sampling at the Genetic Counselling Clinic 
held every Wednesday at the Breast and Plastic Clinic (as discussed in 1.6). The Genetic 
Counselling Clinic is run by the Department of Human Genetics, National Health Laboratory 
Service (NHLS) and University of the Witwatersrand (WITS). Subjects who underwent 
genetic counselling as part of their routine management were asked to participate in the 
study after their consultation by giving consent for the use of their genetic counselling files in 
a research study. Informed consent for the use of these files was obtained (refer to Appendix 
2 for information sheet and consent form). Subjects who were seen at the clinic between 
June 2010 and June 2011 were approached. These subjects also had the option of having 
blood taken for DNA banking and signed written consent for future diagnostic and research 
testing in this regard.  
2.1.1 Sample 
From the inception of the Genetic Counselling Service at the Breast and Plastic Clinic (CHB) 
in June 2010 until June 2011, 60 individuals with a confirmed diagnosis of breast cancer 
have been seen for genetic counselling. Forty-five individuals were included in the study 
based on the criteria outlined in section 2.1.1.1 below. Fifteen individuals were excluded 
from the study based on the criteria outlined in section 2.1.1.2.  
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2.1.1.1 Inclusion Criteria 
The following individuals were included in the study: 
 Black South African women who had a confirmed diagnosis of any type of breast 
cancer between the ages of 18 and 50 years. . 
 Black South African women who had a confirmed diagnosis of any type of breast 
cancer at any age in addition to having a first-; second-; or third-degree relative with 
breast and/or ovarian cancer. 
2.1.1.2 Exclusion Criteria 
The following individuals were excluded from the study: 
 Black South African women who had been diagnosed with breast cancer over 50 
years of age and did not have other affected relatives with clinically confirmed breast 
and/or ovarian cancers (0). 
 Women seen at the Genetic Counselling Clinic who were of mixed, white, Indian or 
non-South African ancestry (14).  
 Women whose files did not have sufficient information (1). 
 Women who did not give consent to participate in the study (0). 
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2.2 Methods 
2.2.1 Information and File Collection 
Three-generation pedigrees and risk assessments are performed routinely in genetic 
counselling consultations. Counselling files in the Division of Human Genetics, NHLS and 
WITS should thus contain standard information regarding the counsellee(s). Information that 
was obtained from the genetic counselling files of the 45 selected subjects included: family 
history data of breast and related cancers, previous breast disease history, tumour histology 
and hormonal receptor status and other breast cancer risk factors.  
Information regarding breast cancer histology (e.g. hormonal receptor status and staging 
and grading) was also obtained from the Oncology database with the permission of Dr 
Herbert Cubasch (Head of Breast and Plastic Clinic, CHB). The database is housed at the 
Clinic at CHB and contains information regarding each patient’s diagnosis, histology, and 
treatment plan and surgery details. This information was recorded in the genetic counselling 
files of the counsellees, in addition to the standard information described above. 
It was important that the full names of the subjects were known to the counsellor/s involved 
with the case as well as for the purpose of the research. This information could then be used 
to link other affected relatives involved in the study, making family history data more reliable. 
Once this had been established, a unique “Breast Cancer File Code” was assigned to each 
file in order to maintain anonymity for the study. Each of the 45 files represented an 
individual with breast cancer. No individuals that were selected were found to be related to 
any other individuals. 
The researcher was involved in the majority of the genetic counselling sessions and thus 
obtained consent from these counsellees herself. For those cases in which the researcher 
was not present, the genetic counsellor involved in the case was requested to obtain 
consent from the counsellee. The researcher located all the required patient files in the 
Department of Human Genetics. Additional information was obtained from the Oncology 
database where possible.  
2.2.1.1 Data Collection 
Information obtained from the files was collated on a data collection sheet that had been 
designed for the purposes of the study (refer to Appendix 3). The data collection sheet was 
divided into four main sections: general information regarding the proband(s), family history 
data of the proband(s), breast disease history of the proband(s) and the risk assessment 
data for the proband(s) that was calculated based on the information from the three previous 
categories. 
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General information that was gathered regarding the counsellee(s) included their ages, 
gender, ethnic origin and their employment status. The family history data that were obtained 
included a three-generation pedigree drawing that detailed the ages, dates of birth, types of 
cancer and causes of death for all relevant relatives. These data were used to assess the 
number of affected, unaffected and at-risk relatives within the family. The type, laterality, 
staging, histology and other factors regarding the proband’s breast cancer were recorded 
under the breast disease history heading. Lastly, the risk assessment data was recorded for 
the Claus, Tyrer-Cuzick and Manchester outputs (Sections 1.6.3.2 – 1.6.3.3).      
2.2.2 Terminology 
The following considerations and definitions were taken into account when data were 
obtained from the files: 
The term “proband” referred to the individual affected with breast cancer. The proband was 
also the individual who attended the Genetic Counselling Clinic. The minimum proband age 
for the study was 18 years. The maximum age was 50 years or greater than 50 years if the 
proband had a family history of breast cancer. The proband had to have a confirmed 
diagnosis of breast cancer in order to be considered for participation in the study. 
A “relative” referred to an individual who is related to the proband by blood. This therefore 
excluded individuals who were related to the proband by marriage or adoption. Relatives 
were further stratified as presented in Table 2-1: 
Table 2-1 Degrees of Relation (adapted from Harper, 1998) 
Type: Individuals Considered: 
Amount of Genetic 
Information shared 
with Proband (%): 
First Degree Relative 
(FDR) 
Sibling, dizygotic twin, parent, 
child 
50 
Second Degree 
Relative (SDR) 
Half sibling, uncle, aunt, nephew, 
niece, double first cousin, 
grandparent 
25 
Third Degree 
Relative (TDR) 
First cousin, half-uncle, half-aunt, 
half-nephew, half-niece 
12.5 
 
  
Page | 28  
 
“Ethnic origin” of the proband was determined using first-language as a proxy. This was 
possible since first language is most commonly chosen from one of the 11 official languages 
of South Africa based on its relation to a kinship or ethnic population group (Byrnes, 1996). 
Language was determined from patient-reported information during the counselling session 
as obtained from the counselling file. Pedigree Analysis  
In order to explore the relationship between family history and the occurrence of breast 
cancer in black South African women, the family histories of the subjects were examined and 
categorized based on the number of affected and unaffected first- second- and third-degree 
relatives. Other factors were also examined such as the age of onset of cancers in these 
relatives, the types of cancer as well as the age and cause of death.   
In order to assess the number of affected, unaffected and at-risk relatives in a family, the 
pedigree was redrawn on the data sheet and analysed. In instances where a proband had 
more than one consultation, the most recent pedigree was utilised. No identifiable 
information (names or surnames) were included on the pedigree for the relatives of the 
proband.  
“At-risk female relatives” referred to as first-, second- and third- degree relatives, were 
deemed to be at an increased risk of developing breast cancer in their lifetime based on the 
numbers of affected members of the family (refer to Figure 2-1). The at-risk female relatives 
included relatives from the proband’s generation as well as the generations directly above 
and below the proband. “At-risk” relatives were not age stratified. Consequently, some 
individuals who were classified as “at-risk” were young. Males were excluded from the “at-
risk” group based on the consideration that breast cancer is 100 times more common in 
women than in men (Bernstein, 2003). 
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Figure 2-1 Hypothetical illustration of the first-, second- and third-degree females relatives of a proband who would be 
considered at an increased risk of developing breast cancer in their lifetime. 
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2.2.3 Risk Assessment  
The data collected from the personal and family history information were used for risk 
calculations. Initially, baseline risk was assessed through an examination of the pedigree 
only. Following this, pedigree information and personal breast disease history was used to 
calculate risks using the various tools. In order for the results to be consistent and 
comparable to one another, lifetime risks were calculated for a hypothetical first-degree 
relative of the proband who was twenty-years old and mutation risks were calculated for the 
family. These risk assessments were carried out using three different methods, namely: The 
Claus Model, the Tyrer-Cuzick Model and The Manchester scoring system. These risk 
assessments were compared to the baseline risk according to the pedigree analysis. 
2.2.3.1 Baseline Family History Risk Assessment 
Probands were differentiated into three categories based on their age and/or family histories. 
The criteria for inclusion into an average, moderate or high risk category are outlined in 
Table 2-2.  
Table 2-2 Criteria for the stratification of individuals and families into risk groups according to 
family history (adapted from Lee, Beattie, Crawford, et al., 2005) 
Risk 
Category: 
Criteria: 
Average 
One relative with breast cancer over 50 years old 
One breast cancer under 50 years old in a second degree relative with an 
otherwise negative family history 
One cancer in the proband or in a FDR/SDR that is not a hereditary “red-flag” 
cancer site (e.g. ovarian, fallopian tube, melanoma, colorectal, pancreatic, 
gastric, bile duct, uterine, or “abdominal”) 
Moderate 
One breast cancer under age 50 years in a first or second degree paternal 
relative 
Any one of the “red-flag” cancers listed above in the proband or in one FDR 
Family history of two or more breast cancers at any age 
High 
Two or more breast cancers with at least one under age 50 years on the same 
side of the family 
Proband with breast cancer under the age of 40 years 
Male breast cancer 
Two or more “red-flag” cancers in the proband or on one side of the family 
Proband has breast or colorectal cancer under the age of 50 or ovarian cancer 
at any age and the maternal/paternal history is unknown 
Breast and ovarian cancer on the same side of the family 
Any family member with bilateral breast cancer 
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2.2.3.2 The Claus Model 
The Claus model is an epidemiological model. The model calculates the lifetime risk of 
developing breast cancer for a relative of the subject. For consistency, a hypothetical 20-
year old FDR of the proband was used for calculations. It relies on a set of tables that predict 
the occurrence of breast cancer at different ages depending on the occurrence of breast 
cancer in first- and second- degree relatives and their ages of onset of cancer (refer to 
Appendix 4 for Claus Tables frequently used in this study). The Claus model does not take 
into consideration any non-familial breast cancer risk factors (Rubinstein, et al., 2002).  
2.2.3.3 The Tyrer-Cuzick Model 
The Tyrer-Cuzick Model calculated a risk for both outputs (i.e. lifetime and mutation risks). 
This computer model evaluates risk based on extensive family history, endogenous 
oestrogen exposure and benign breast disease. There were three outputs of the model, 
namely, a 10-year risk prediction, a beyond 10-year risk prediction (lifetime risk) as well as 
the mutation risk output (Boughey, et al., 2010). The mutation risk probabilities are 
calculated with consideration of an autosomal dominant pattern of inheritance and thus 
would not exceed 50% for a 20 year old FDR.  
2.2.3.4 The Manchester Scoring System 
The Manchester scoring system was utilized in order to estimate the risk of the proband’s 
family harbouring a mutation in one of the two main predisposing breast cancer genes 
(BRCA1 and BRCA2). A score is assigned for each cancer on the same side of the family 
(i.e. in a direct blood line). Scores for BRCA1 and BRCA2 are combined to give an overall 
score (refer to Appendix 4 for Manchester Scoring System) (Antoniu, et al., 2008).  
2.2.4 Risk Assessment Consistency 
Each of the models used to analyse risk in this study provided an output in an alternate 
format (i.e.: categorical; ratio; percentage; score). In order to evaluate whether or not the risk 
outputs of these models were consistent, it was necessary to convert all of the output data 
into a single format. For the purposes of this research, a categorical format was selected in 
the form: average risk, moderate risk, or high risk. The output data were converted and 
categorised based on the information outlined in Table 2-3 below. Following this, further 
statistical analyses could be done in order to compare the consistency of these models.  
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Table 2-3 Information used to convert various risk assessment data outputs into a standard 
format for use in statistical comparisons 
 
Original Risk 
Output Format: 
Alteration To: 
Reference: 
Average Moderate High 
Family History Risk Categorical N/A N/A N/A N/A 
Claus Output 
Ratio (converted 
to percentage) 
<17% 17-30% ≥30% NICE (2006) 
Tyrer-Cuzick Output 
1 (Lifetime Risk) 
Percentage <17% 17-30% ≥30% NICE (2006) 
Tyrer-Cuzick Output 
2 (BRCA Mutation 
Risk) 
Percentage <3% 3.0-9.9% ≥10% 
Evans, G., 2011, 
personal communication, 
18 July 
Manchester Output Score <10 10-20 >20 
Evans, G., 2011, 
personal communication, 
18 July 
 
2.3 Data Analysis  
Data analysis was performed by examining the similarities and differences in the family 
histories of the black women who have had breast cancer. The risks that were generated by 
the three models as well as the baseline risk assessments were compared and contrasted in 
order to determine their consistency.  
The data generated were entered into a database and analysed using descriptive statistics. 
Frequency distributions, central tendency statistics, associations and inference were also 
employed to gain an understanding of the study data and examine whether any patterns 
emerged from the immediate group of data. Inferential statistics were also employed. 
Pearson correlations were calculated to examine the relationships between age and stage at 
diagnosis of breast cancer, the risk outputs of the Claus and Tyrer-Cuzick models and 
finally, the risk outputs of the Tyrer-Cuzick model and the Manchester Scoring system. 
Lastly, in order to evaluate the consistency across all types of risk assessment, a single-
factor ANOVA was performed.  
Figure 2-2 presents a summary of the subjects chosen as well as some of the methods used 
in this study.  The study design did not allow for the determination of absolute risks for these 
patients and their relatives. However, it will form the basis of a future study that will aim to 
investigate the accuracy of these risk predictions by performing BRCA screening on those 
families who appear to have moderate to high risk for having an inherited form of breast 
cancer. 
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Figure 2-2 Summary of subject selection, data collection and methodology 
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3 RESULTS 
Results were generated from the 45 breast cancer subject files. This chapter will highlight 
the results obtained from the analysis of data collected from these files. The chapter will 
begin with outlining the findings regarding the subjects’ demographics. Following this, a 
generalised breast disease profile of the subjects will be delineated. The data regarding 
family histories of the subjects will be discussed. The main findings with respect to the 
performance of risk assessment tools in black women with breast cancer will be presented. 
Lastly, the consistency of these tools when used in this population will be assessed.  
3.1 Demographics 
All the probands included in the study were black females who were diagnosed with breast 
cancer at 50 years or younger. No women diagnosed with breast cancer over the age of 50 
years but who had a family history of breast and/or ovarian cancers were identified during 
the time period of the study. Further, no male probands with breast cancer were identified for 
inclusion in the study. 
Of the 45 probands, only two (4%) attended their genetic counselling consultation at the 
Breast and Plastic Clinic, CHB, with a support person. One proband attended with her sibling 
and the other with her mother. All other probands (n=43; 96%) attended alone. Twenty-five 
of the 45 probands (56%) reported that they were unemployed at the time of the 
consultation. Seventeen subjects (38%) reported that they were employed and three 
subjects (7%) reported that they had been previously employed but were not working at the 
time of the consultation. 
3.1.1 Age Range 
The age of the probands at the time of their consultations ranged from 24 to 59 years with a 
median age of 39 ± 7.13 years and a mode of 34 years. The age at breast cancer diagnosis 
of the probands is illustrated in Figure 3-1. The age at diagnosis ranged from 23 to 50 years 
with a median age at diagnosis of 38 ± 6.41 years and a mode of 38 years.  
3.1.2 Ethnicity 
Information regarding the first language of the subjects was available for 30 of the 45 
subjects (67%). This information was used as a proxy for ethnicity / tribal origin (as 
discussed in section 2.2.2.1). The distribution of ethnicities is demonstrated in Figure 3-2. 
The majority of the probands (n=12; 40%) indicated that isiZulu was their first language. The 
second largest group of probands (n=6; 20%) consisted of individuals who spoke isiXhosa 
as their first language and the third largest group indicated that seSotho was their first 
language. No subjects reported having isiNdebele or siSwati as their first-languages.     
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Figure 3-2 Age at breast cancer diagnosis of the probands (n=45) 
Figure 3-1 Ethnic origins of the individuals (n=30) who attended 
breast cancer genetic counselling consultations 
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3.2 Breast Disease Profile 
Of the 45 breast cancer diagnoses made in the probands, greater than 95% (n=43) were 
found to have unilateral disease while the remainder had bilateral disease (n=2; 4%). In 
addition, the majority (n=44; 98%) of the breast cancers were ductal carcinomas. Lobular 
carcinomas accounted for 2% (n=1) of the probands.   
Seven probands (16%) were found to have an additional cancer other than breast cancer. 
Upon closer inspection, four of these were found to be metastases (two in the lungs, one on 
the sternum and one in an unreported location). The three remaining probands reported an 
additional primary cervical cancer. It is unsure whether or not this is related to the pattern of 
inherited breast cancer in this population.  
The majority of probands (n=32; 71%) underwent therapeutic mastectomies as part of their 
treatment protocol. A further 16% of probands (n=7) were treated with breast conservation 
therapy. The remainder of patients (n=6; 13%) had received only neo-adjuvant treatment 
(chemotherapy and/or radiation) at the time of their genetic counselling consultation and 
were awaiting a surgical and/or management decision.  
3.2.1 Stage at Presentation 
Breast cancer TNM staging and grading information was obtained from 41 of 45 (91.11%) 
proband files. Stage was assigned according to AJCC guidelines as discussed in Section 
1.1.3. Figure 3-3 illustrates the number of individuals within the cohort who presented with 
each stage of disease.  As can be seen from this figure, the majority of individuals (n=36; 
87%) had stage II or III disease at the time of presentation.  
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The Pearson correlation co-efficient for age and stage at diagnosis was 0.12. This could be 
considered a positive but weak relationship. In other words, when age at diagnosis 
increases, stage at diagnosis also increases. Age at diagnosis accounted for 1% of the 
variance in stage at diagnosis. 
3.2.2 Receptor Status 
Information regarding ER, PR and HER2 status was obtained from 40 of the 45 (88.89%) 
proband files. Data were stratified according to the phenotypes outlined by Onitilo, et al., 
(2009). Table 3-1 illustrates the number of probands that were assigned to each receptor 
phenotype. Of particular interest is 40% of probands (16/40) had triple receptor positive 
phenotypes (ER/PR+; HER2+) and 20% of probands (8/40) had triple receptor negative 
(ER/PR-; HER2-) phenotypes.  
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Table 3-1 Receptor Phenotypes of Probands 
 
3.2.3 Hormonal Factors Contributing to Breast Disease 
Some hormonal factors that are known to contribute to the risk of developing breast cancer 
were examined in the probands. Data were not available for all probands regarding each of 
the factors.  
 The age at menarche of the probands ranged from 13 to 20 years with a median age 
of 15 ± 2.16 years and a mode of 13 years (ascertained from 27 of 45 proband files).  
 Sixty percent (n=15) of probands reported using assorted types of contraception for 
various durations while the other 40% (n=10) reported no use of contraception 
(ascertained from 25 of 45 proband files). Analysis of the types of contraceptives 
used could not be performed due to insufficient data.  
 The age at first pregnancy of the probands ranged from 15 to 34 years with a median 
age of 21 ± 4.72 years and a mode of 19 years (ascertained from 39 of 45 proband 
files). The remaining 6 probands did not have any children.  
 The total duration of breast feeding (for all children) by probands ranged from 4 to 96 
months with a median duration of 24 ± 27.44 months and a mode of 4 months. Six 
women reported never having breast fed (ascertained from 24 of 45 proband files). 
There are insufficient data on these factors within the population of interest in order to be 
able to comment on the manner in which these factors influence breast cancer risk.  
  
Receptor Phenotype: 
Probands Exhibiting Phenotype 
N % 
ER/PR+ ; HER2+ 16 40 
ER/PR+ ; HER2- 9 22 
ER/PR- ; HER2+ 7 18 
ER/PR- ; HER2- 8 20 
Total 40 100 
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3.3 Pedigree Analysis 
The numbers of affected and at-risk relatives were calculated in the 45 probands’ families. In 
total, 76% of probands (n=34) had no family history of breast and/or ovarian cancer. 
Information from the pedigree analysis is illustrated in Table 3-2. The ratio of first- and 
second- degree affected family members to at-risk females were slightly raised compared to 
the 1 in 55 general population risk of breast cancer in the black South African population. 
The calculation of these ratios was performed without including the affected probands as this 
would have given a biased representation of family history in these families. Nevertheless, 
these figures do not reflect the approximate 20-30% rate of affected family members on one 
side of a family that would be expected from a high risk cohort showing autosomal dominant 
inheritance and a penetrance of 40-60%. 
3.3.1 At-Risk Female Relatives 
In a total of 921 unaffected first-, second, and third- degree relatives of the probands, 400 
female relatives were deemed to be at an increased risk of developing breast cancer in their 
lifetime (refer to section 2.2.3 as well as figures 2-1 and 2-2). The mean number of at-risk 
female relatives per family was calculated as being 8.89 ± 3.83 (range: 2-18).  Males were 
not considered in the calculation of at-risk relatives because of their significantly decreased 
risk for breast cancer.   
Table 3-2 Numbers of affected and at-risk female relatives of probands 
*SD – Standard Deviation  
3.3.2 Affected Relatives 
Eleven of the 45 probands (24%) were found to have other family members affected with 
breast cancer. As can be seen in Figure 3-4, seven probands (64%) had one relative who 
also had breast cancer and 4 probands (36%) had two relatives who also had breast cancer 
(these four pedigrees are illustrated in Figure 4-2 and Figure 4-3 in the discussion). None of 
Degree of 
Relation 
Affected Relatives At-Risk Female Relatives 
Ratio of 
Affected: At-Risk 
Females 
N 
Mean number of 
individuals per 
family ± SD* 
N 
Mean number of 
individuals per 
family ± SD* 
FDR 4 0.09 ± 0.29 126 2.80 ± 1.69 ± 1:31 
SDR 6 0.13 ± 0.40 220 4.89 ± 2.85 ± 1:37 
TDR 5 0.11 ± 0.38 54 1.20 ± 2.61 ± 1:11 
Total: 15 0.33 ± 0.64 400 8.89 ± 3.83 1:27 
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the probands had more than two other relatives with breast cancer diagnosed in the family. 
No confirmed occurrence of ovarian cancer was reported in any of the probands’ relatives.  
 
 
 
 
 
 
 
The family pedigrees of the four probands who were found to have two affected relatives are 
illustrated below (Figure 3-5 and Figure 3-6). In Figure 3-5A, there is a male affected with 
breast cancer as well as a half-sister of the proband, diagnosed with breast cancer at a 
young age. In Figure 3-5B, the proband herself is considered high risk because of her young 
age at diagnosis and her TNBC status. The proband’s mother does not have breast cancer 
and therefore has the potential to be a non-penetrant carrier of a BRCA mutation considering 
both her sister and mother had breast cancer (both diagnosed at 45 years).  
In Figure 3-6C, the proband is again considered to be high risk since her diagnosis was 
made at 39 years of age and she has TNBC. The high risk status of this family is confirmed 
by the diagnosis of the proband’s sister at age 27 as well as her grandmother’s diagnosis. 
Her mother was diagnosed with leukaemia, a cancer not commonly associated with HBOC 
but nevertheless relevant since it is associated with another cancer predisposition syndrome, 
Li Fraumeni syndrome. In fact, this family fulfils diagnostic criteria for Li Fraumeni syndrome 
molecular testing (Tinat, et al., 2009). Lastly, in Figure 3-6D, the young age at diagnosis of 
the proband’s first cousin as well as the bilateral breast cancer diagnosis in her second 
cousin makes this a high risk family. 
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Figure 3-5 Family history pedigrees of four probands who were found to have two 
affected relatives: (A) Proband with an affected half-sister (SDR) and an affected 
nephew (TDR). (B) Proband with an affected maternal aunt (SDR) and an affected 
maternal grandmother (SDR) 
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Figure 3-6 Family history pedigrees of the four probands who were found to have 
two affected relatives: (C) Proband with an affected sister (FDR) and an affected 
grandmother (SDR). The proband’s mother had leukaemia. (D) Proband with an 
affected cousin (TDR) and an affected second cousin with bilateral disease.  
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Seventy-three percent of the probands (8/11) who had a family history of breast cancer were 
diagnosed with breast cancer under the age of 40 years. None of these probands had 
bilateral disease. The age at breast cancer diagnosis in the affected relatives of the 
probands ranged from 23 to 74 years with a median age of 42.5 ± 15.3 years and a mode of 
45 years. A single relative of a proband affected with breast cancer was a male (Figure 4-
2A) and a single relative had bilateral breast cancer (Figure 4-3D).  Eighty percent (12/15) of 
affected relatives were related to the proband on the maternal side; however a significant 
number of probands had reported not having information on the paternal side of the family.   
A total of 24 other types of cancers were self-reported in the family histories of the probands. 
The most common type of cancer indicated in the families was throat cancer (33%) followed 
by “womb” cancer (25%). The breakdown of these types of cancers is demonstrated in Table 
3-3.  
 
Table 3-3 other types of cancers that were reported in the family histories of the probands 
 
 
 
 
 
 
 
 
 
*Cancers that may be associated with HBOC (if “womb” is “ovarian cancer” as opposed to “uterine cancer” or “cervical cancer”) 
  
Type of Cancer: 
Affected Individuals 
N % 
Brain 1 4 
Cervical 1 4 
Leukemia 1 4 
Prostate* 3 14 
Stomach* 1 4 
Throat 8 33 
Tongue 1 4 
Unknown 2 8 
“Womb”* 6 25 
Total 24 100 
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3.4 Risk Assessment 
3.4.1 Baseline Family History Risk Assessment 
Family histories were additionally analysed in order to group the probands’ families into 
average, moderate or high risk of having an inherited cancer syndrome (as outlined in Table 
2-2). The following breakdown resulted for the 45 probands assessed: 
 No families were found to be at average risk 
 Fifteen (33%) families were found to be at moderate risk 
 Thirty (67%) families were found to be at high risk 
Twenty of the 30 (67%) high risk families were placed in this category only as a result of the 
young age at diagnosis of the proband (less than 40 years) but were not found to have any 
other affected relatives. An additional 7 families (23%) were placed at high risk based on the 
young age of the proband in addition to the presence of a family history. The remaining three 
families (10%) were placed in a high risk category based on the presence of a family history 
alone; the ages of the probands in these three families were all older than 40 years.  
3.4.2 Claus Model 
The Claus model of risk assessment (see Appendix 4) was used to calculate the lifetime risk 
of developing breast cancer for a hypothetical 20 year-old FDR of the proband. The lifetime 
risks for these individuals are presented in Figure 3-5.  
Most individuals were assigned a Claus risk based only on a single affected relative (i.e.: the 
proband). As can be seen, 73% (33/45) of these individuals were assigned a risk of between 
14.3% (1 in 7) and 20% (1 in 5). Significantly less individuals (3/45; 7%) were given a risk of 
25% or greater. Eight individuals could not be assigned a risk using the Claus model as an 
appropriate Claus Table was not available for their particular family structure. Family 
structures that excluded the use of the Claus tables were those that had more than two 
affected relatives or had a clear pattern of autosomal dominant inheritance.     
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Figure 3-7 Lifetime risks of developing breast cancer for 20 year-old FDR's of probands 
calculated by the Claus Model of Risk Assessment (n=45) 
3.4.3 Tyrer-Cuzick Model 
The Tyrer-Cuzick Model is a software program that is used to calculate 10-year risks and 
lifetime risks for a 20 year-old FDR of a proband as well as a mutation risk for the proband’s 
family. Table 3-4 outlines the ranges and means calculated for all outputs from the Tyrer-
Cuzick Model. Table 3-5 shows how 20 year-old FDRs of the probands are stratified for 
lifetime risk by the Tyrer-Cuzick model.   
Table 3-4 Ranges and means of risk outputs from the Tyrer-Cuzick model 
Risk Output Range (%) Median Mode 
20- year old FDR 10-year 0.13 - 1.68 0.18 0.22 
Lifetime 17.74 - 33.99 18.95 17.84 
Family BRCA1 mutation 0.16 - 17.25 0.82 0.32 
BRCA2 mutation 0.24 - 4.79 0.72 0.26 
Combined BRCA 0.41 - 21.05 1.56 0.58 
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Table 3-5 Lifetime risk of developing breast cancer generated for a hypothetical 20-year old 
FDR from the Tyrer-Cuzick model 
Lifetime Risk (%) 
Individuals 
Number Percentage 
17.00-17.99 5 11 
18.00-18.99 20 44 
19.00-19.99 12 27 
≥20.00 8 18 
Total 45 100 
 
The Tyrer-Cuzick software calculated mutation risks for BRCA1 and BRCA2 independently. 
These scores were then combined in order to give an over-all risk of each family harbouring 
a deleterious BRCA mutation as described in Figure 3-6. As can be seen in Figure 3-6, the 
majority of families (n=19; 42%) were found to have a combined BRCA mutation risk 
between 1.00% and 1.99%. Only 11% (n=5) of families had a score greater than 4%.  
  
 
 
 
 
 
 
 
 
  
Figure 3-8 Combined BRCA mutation risks for the families of the 
probands as predicted by the Tyrer-Cuzick model (n=45) 
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3.4.4 Manchester Scoring System 
The Manchester scoring system was utilised to calculate the risk of the probands’ families 
having a BRCA mutation that could predispose them to the development of hereditary breast 
and/or ovarian cancer. Results of this risk assessment programme showed there to be a 
range of Manchester scores from 2 to 24 points with a median score of 8 ± 5 and a mode of 
8. The majority of families (n=23; 51%) had a Manchester score of between 5 and 10. Only 3 
families (7%) were assigned a Manchester score of greater than 20 points. All three of these 
families had multiple affected relatives.    
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3.5 Analysis of Risk Assessment Model Consistency 
In order to be able to compare the results of each of the risk assessment models to one 
another as well as to the initial baseline family history assessment, it was necessary to 
convert each of the data outputs into a single format (as discussed in section 2.2.5). The 
distribution of relatives and families to average, moderate or high risk categories after 
conversion is illustrated in Figure 3-7.  
 
It was possible to analyse the consistency between models measuring the same variables 
(e.g. between the Claus model and the Tyrer-Cuzick [lifetime risk] model or between the 
Manchester model and the Tyrer-Cuzick [BRCA mutation risk] model). 
3.5.1 Claus Model vs. Tyrer-Cuzick Model  
Both of these models calculate the risk for a 20 year old FDR of developing breast cancer in 
her lifetime. There was a strong positive correlation between these two risk model outputs [r 
(37) =0.90]. In other words, as the risk calculated for a 20 year old first degree relative using 
the Claus tables increased, so too did the risk increase when the Tyrer-Cuzick model was 
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used. The variance in the models was calculated to be 82%. This is illustrated in Figure 3-8 
(A).  
3.5.2 Tyrer-Cuzick Model vs. Manchester Scoring System 
Similar to the above comparison, there was a moderately positive correlation between the 
two models that both calculate for the BRCA mutation risk of a family [r (45) =0.65]. This 
suggests that as the BRCA-related risk calculated for the family by the Tyrer-Cuzick model 
increases, so too does the risk calculated by the Manchester model. This relationship is less 
well correlated than the relationship between the lifetime risks calculated by the Claus and 
Tyrer-Cuzick models. The variance in the model was calculated to be 43%. This is illustrated 
in Figure 3-8 (B). This graph seems to indicate that these two risk assessment tools become 
less correlated at higher risks, while they appear better correlated at lower risks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 0.2383x + 14.583
R² = 0.8153
0.00
5.00
10.00
15.00
20.00
25.00
30.00
0 10 20 30 40 50
L
if
e
ti
m
e
 R
is
k
 c
a
lc
u
la
te
d
 b
y
 T
y
re
r-
C
u
z
ic
k
 M
o
d
e
l 
(%
)
Lifetime risk calculated by Claus Model (%)
y = 0.4922x - 1.7389
R² = 0.4288
-5
0
5
10
15
20
25
0 10 20 30C
o
m
b
in
e
d
 B
R
C
A
 m
u
ta
ti
o
n
 r
is
k
 
c
a
lc
u
la
te
d
 b
y
 T
y
re
r-
C
u
z
ic
k
 
M
o
d
e
l 
(%
)
Combined BRCA mutation risk calculated by Manchester 
Scoring System (%)
Figure 3-10 Comparison of risk output between (A) the 
Claus model and the Tyrer-Cuzick model and (B) the Tyrer-
Cuzick model and the Manchester scoring system 
A 
B 
Page | 50  
 
3.5.3 Comparison of All Models 
On inspection of the model outputs after they had been coded, the relatives/family of only a 
single proband were placed in the same risk category (high risk) by the baseline risk 
assessment, the Tyrer-Cuzick lifetime and mutation risk models and the Manchester scoring 
system. The Claus model could not be used in this family due to the fact that there was no 
appropriate table. All other risk outputs were inconsistent among the various models. To 
highlight this finding, an Analysis of Variance (ANOVA) was performed.  
The ANOVA (illustrated in Figure 3-9) that was used to evaluate the consistency of the 
various risk assessment platforms indicated that there was a significant difference among 
the risk predictions made by each of the programmes at the p<0.05 level [F (4,212) = 64.78, 
p = 1.03-35]. This illustrated that the risk assessment programmes gave inconsistent risks for 
each proband in the cohort.  
The family history assessment appears to have little variance with the Claus model. In turn, 
the Claus and Tyrer-Cuzick lifetime risk models appear to show less variance between them. 
Similarly, the Tyrer-Cuzick mutation risk model and the Manchester scoring system also 
appear to show less variance between them. Both the Tyrer-Cuzick model and the 
Manchester scoring system appeared to be markedly variable from the family history 
assessment. 
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Figure 3-11 Single- Factor ANOVA analysis indicating the inconsistency of the various breast 
cancer risk assessment platforms 
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4 DISCUSSION 
The results of this study have given an overview of the demographics of a sample of the 
patients seen for genetic counselling at the Breast and Plastic Clinic, CHB. In addition, the 
results have illustrated the profile of breast disease in the probands as well as numerous 
factors concerning their family histories. The results concluded with an examination of the 
various risk assessment tools that were utilised to make predictions regarding lifetime and 
mutation risks in this population.  
The following chapter will discuss various aspects of the relevance of these results. Further, 
their importance for future research will be discussed and their potential applicability to the 
genetic counselling of black women with breast cancer will be outlined.   
4.1 Demographics 
Black South African women were the population of interest in this study. Specifically, black 
South African women who had been diagnosed with breast cancer at a young age (<50 
years) were examined. The demographic data relating to this cohort were analysed as 
follows. 
4.1.1 Socioeconomic and Cultural Factors 
It is important to ascertain whether or not the probands in this study were representative of 
the larger population of urban black South African women living in the Soweto area. 
Accordingly, it was necessary to examine certain socioeconomic factors, the ethnic/tribal 
origins of the probands as well as the setting in which the study took place.    
The unemployment rate in the cohort was found to be 55.56%. This figure is consistent with 
the general rate of unemployment in Soweto, which was quoted as 53% in 2001 
(Department of Economic Development [DED], 2009).  
The probands were ascertained from Chris Hani Baragwanath Hospital (CHB), the main 
tertiary hospital in the Soweto area, and the largest in the country. In addition, referrals are 
made to CHB from all parts of the province of Gauteng.  
Gauteng is a linguistically diverse area and no particular language is dominant. Having said 
this however, 21.5% of people in Gauteng report isiZulu as their mother tongue (Media Club 
South Africa, 2011). IsiZulu was found to be the commonest language spoken by the 
probands. In fact, 40% of probands (12/30) reported isiZulu as their first language. This is 
roughly double the figure given for Gauteng. It is difficult to comment on this difference, as  
the  sample is small. Most of the other languages were represented in the cohort with the 
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exception of isiNdebele and siSwati, which are considered minority official languages (Media 
Club South Africa, 2011). 
Although no data on education and income were collected in the present study, discussions 
were held with genetic counsellors, who worked in the cancer clinic, on these issues. They 
made some interesting  observations. One such observation was that in general, the women 
they counselled seemed to be quite well educated and aware of breast cancer surveillance 
and detection strategies. This would, to a certain extent, be expected as it is the younger 
generation in urban settings who have been exposed to breast cancer awareness 
campaigns and education at many levels (e.g. school and media). On the contrary, we would 
suspect that the less aware patients living in rural areas are not presenting to the clinic and 
are remaining undiagnosed and untreated.  
A second observation regarding the women with breast cancer who attend the clinic has also 
been made by the genetic counsellors regarding their attitudes towards western and 
traditional medicine. A portion of women who come to the clinic for initial evaluations often 
default from treatment once they have been given a breast cancer diagnosis. These women 
describe returning to the clinic after having consulted a traditional healer without apparent 
results. This may, to a small extent, explain the trend towards later stage at breast cancer 
presentation, as seen in other African women (Walker, et al., 2004).           
It seems apt to suggest from the above, that the cohort of women who were studied for the 
purposes of this research are broadly representative of the urban population from whence 
they originate with respect to the socioeconomic and cultural aspects described above. As 
such, the findings of this study can be extrapolated to this broader population in general (i.e. 
urban black South African women with breast cancer under the age of 50 years). Since there 
were insufficient data regarding the education, employment and income of these individuals, 
it is not possible to extend the based on these factors.    
4.1.2 Age at diagnosis 
The aim of this study was to target women who were thought to be at an increased risk of 
having an inherited cancer syndrome. The selection of probands appropriate for this study 
was therefore biased towards younger women diagnosed with breast cancer rather than 
older women who had breast cancer in addition to a family history. This is because in 
general in most populations, young age at diagnosis is used as a means of identifying those 
individuals who are at an increased risk of developing cancer. In other words, young age at 
diagnosis is a risk factor for an inherited cancer syndrome.  
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African populations have a different age distribution with a low median age compared to first 
world populations (Akaralo-Anthony, et al., 2010) this distribution is also applicable to the 
local black population of South Africa. Figure 4-1 depicts the mid-year population estimates 
for (A) black and (B) white South African women, distributed by age (Statistics South Africa, 
2011). This shift towards a younger median age is particularly noticeable in comparison with 
an equivalent Caucasian population. The trend of a lower median age can, to a limited 
extent, be corroborated by data from the Breast and Plastic Clinic (CHB) itself. This data 
shows a peak of breast cancer diagnoses between 35 and 40 years of age as well as 
between 50 and 55 years of age (Cubasch, H., 2011, personal communication, 20 June).  
In consideration of the above, it seems possible to conclude that perhaps the use of young 
age at diagnosis of breast cancer may not be a good criterion in a population where the age 
distribution is so significantly shifted, as relatively more young patients with sporadic breast 
cancer might be expected. 
It is important to note that the age of onset of breast cancer in this population could also be 
consistent with a diagnosis of Li Fraumeni Syndrome (LFS), an inherited cancer syndrome 
that is associated with mutations in the p53 tumour suppressor gene. Probands who are 
diagnosed with premenopausal breast cancer before the age of 46 years old can be 
considered eligible for p53 molecular genetic testing according to the 2009 Chompret 
Criteria for LFS if found in the presence of other LFS associated tumours (such as: soft 
tissue sarcoma, osteosarcoma, adrenocortical carcinoma and leukaemia) in the family 
history and also in the absence of BRCA mutations (Tinat, Bougeard, Baert-Deusrmont, et 
al., 2009).  
  
Figure 4-1 2011 Mid-year population estimates for (A) black and (B) white South African 
Women (Statistics South Africa, 2011) 
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4.2 Breast Disease Profile 
There are a number of observations that can be made regarding the breast disease profiles 
of the population of interest. In general the breast disease profiles of the cohort studied 
tended to be consistent with breast disease profiles of women with breast cancer in general 
(Ely and Vioral, 2007) and with women from African populations specifically (Akaralo-
Anthony, et al., 2010; Stark, et al., 2010; Walker, et al., 2004).  
Greater than 95% of probands in the cohort were diagnosed with unilateral ductal 
carcinomas. This is consistent with a reported incidence of bilateral breast cancer of 7.1% 
and therefore a related incidence of unilateral breast cancer of 92.9% in a Caucasian 
population (Smith, 1986). No comparable data are available regarding the incidence of 
ductal carcinomas and unilateral carcinomas in African populations. There were very few 
occurrences of bilateral breast cancers in the probands and in their affected relatives. This 
paucity is interesting since bilateral breast cancers are strongly indicative of a possible 
inherited breast cancer condition. This could potentially provide further evidence for the 
occurrence of sporadic breast cancers in this young cohort rather than inherited breast 
cancer susceptibility. Further, the one proband who was diagnosed with bilateral breast 
cancer was found to have lobular carcinomas in both breasts. Lobular carcinomas are not 
known to be associated with BRCA mutations but rather with mutations in the CDH1 (e-
cadherin) gene associated with Hereditary Diffuse Gastric Cancer (Fitzgerald, Hardwick, 
Huntsman, et al., 2009). This finding highlights the idea that inherited cancer susceptibilities 
are likely to exist in this population and importantly, this may not be limited to BRCA 
mutations but rather may include a variety of other genes. A similar suggestion was put 
forward by Fackenthal, et al. (2011) who recommended that multiple genes as well as 
relevant genomic pathways be examined in their Nigerian cohort as well as women of 
African ancestry in general.   
The incidence of cervical cancer as a second primary in three of the probands was 1 in 15. 
This is double the overall incidence of cervical cancer in black South African women 
reported in 2002 as 1 in 30 (National Cancer Registry, 2009). Despite the small sample size, 
this was an interesting observation, however, possibly co-incidental and difficult to interpret. 
There is no concrete evidence to suggest that cervical cancer may be a component of 
inherited breast cancer syndromes. Also, the relationship between breast cancer and human 
papillomavirus (HPV) infection has not been determined (Wang, Chang, Wang, et al., 2011).  
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There was a high degree of consistency between the stage at presentation of the cohort and 
the general group of women who were seen at the Breast and Plastic Clinic, CHB in general 
over a period from 2007 to 2011 (Cubasch, H., 2011, personal communication, 20 June). In 
both instances, 87% of the patients were found to be either stage II or III at diagnosis.  
Despite the limited data that was captured regarding the hormonal factors of the breast 
cancer probands, it seems reasonable to suggest that the observations made (section 3.2.3) 
were similar to expected trends from other African women. This is unsurprising since there 
are no obvious reasons for this population to be at an increased breast cancer risk as a 
consequence of environmental or hormonal factors. One possible exception is the use of 
injectable progesterone contraceptives, a common practice in this population. The role of 
progestins in breast cancer risk is controversial however some research does indicate a 
carcinogenic effect, particularly of the breast (Sitruk-Ware and Nath, 2010). The use of this 
type of contraceptive and its correlation with breast cancer occurrence could not be 
evaluated in this research due to the paucity of data.  
An increased incidence of triple receptor negative breast cancer (TNBC; negative for 
expression of ER, PR and HER2 receptors) has been well documented in African 
populations (Bird, et al., 2008; Huo, et al., 2009; Stark, et al., 2010). Twenty percent of the 
cohort were characterised as TNBC. This figure appears to be consistent with the incidence 
of TNBC in African American populations which is ±25% (Stark, et al., 2010). The reasons 
behind this increased incidence of TNBC are not fully understood. However, recent research 
has suggested that higher parity (number of live-born children) and lower prevalence of 
breast feeding in African American women is correlated with an increased incidence of 
estrogen and progesterone receptor negative expression phenotype (Palmer, Boggs, Wise, 
et al., 2011). Whether this is true in the local context remains to be seen and further 
research is indicated in this regard. This is especially important since TNBC is seen as a 
predictor of an inherited breast cancer. This could be useful in the absence of other typical 
predictors as is the case with this cohort, if this is true. However, again, the role of 
environmental factors needs to be fully assessed.   
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4.3 Pedigree Analysis 
Information regarding affected, unaffected and at-risk relatives of the probands was 
analysed in order to ascertain the general picture of breast cancer family history in this 
cohort. Overall, there was a significantly decreased amount of affected relatives in this 
cohort. Results indicate that family history information can play a role in predicting which 
individuals are at increased risk for developing breast cancer in this population; however it 
would be essential to examine alternative methods for risk profiling. 
4.3.1 Family Structure  
The four families with a significant family history stood out from the rest since they had 
distinctive characteristics of an inherited breast cancer syndrome.  These four families 
appear to be at high risk irrespective of which risk assessment tools are utilised. It would be 
prudent to suggest that the forthcoming molecular genetic analysis begins with these four 
probands. It is reasonable to suggest that this reinforces the argument put forward 
previously (Section 1.4) that 5-10% of breast cancer cases can be ascribed to an inherited 
predisposition irrespective of the population’s breast cancer burden and age dynamics. This 
would need to be verified by molecular genetic analysis. 
The majority of probands (n=34) did not have any family history suggestive of breast and/or 
ovarian cancer, or other HBOC associated cancers. In fact, it has been observed in the clinic 
that in addition to the absence of confirmed diagnoses of cancers, there was an absence of 
reporting of unverifiable or potential cancers. These individuals were therefore classified as 
moderate or high risk based only on their ages at diagnosis.  
One explanation for the paucity of family history in this cohort could be that the probands 
who had breast cancer were unaware of the occurrence of breast and other cancers in their 
own families. The issue may further be compounded by the fact that many African people did 
not seek the assistance of western medicine in the past and their cancers may have gone 
undiagnosed. In addition, if these people had undergone treatment at state hospitals, it is 
unlikely that their files would be accessible for confirmation. This may then have led to the 
under-estimation of risks in these individuals. 
Another factor contributing to the apparent lack of family history in this population is that 
previously, African women living in a rural setting may have had certain factors that have 
protected them from developing breast cancer. These include a later menarche; earlier age 
at birth of first child and a diet low in animal fats and high in fibre (Vorobiof, Sitas and 
Vorobiof, 2001). Considering that those patients currently being seen at the Breast and 
Plastic Clinic, CHB are living in urban environments and are often the first generation to do 
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so, they are less likely to be protected by these factors. Thus, breast cancer has become 
more prevalent. It is reasonable to suggest that protected individuals from previous 
generations are likely to have died from other causes (such as infectious diseases) at young 
ages, rather than breast cancer. This could have masked any potential family history of 
breast and/or ovarian cancer.   
In consideration of the above discussion one must question whether or not family history is 
an appropriate screening method for genetic counselling and testing in this population. Data 
from this study seem to suggest that although most of the breast cancer diagnoses in this 
cohort may not be inherited, family history must still play an important role in risk 
determination. Having said this however, it seems essential that other factors be examined 
for their impact on risk prediction in this population, in order to ensure that the most 
appropriate individuals are identified for genetic follow-up (counselling and testing).   
Recent research by Southey, Ramus, Dowty, et al., (2011) suggests that morphological and 
histopathological features evident on tumour review (especially for BRCA1 tumours) can be 
used to identify, with higher specificity and sensitivity, those women at greater risk of having 
a BRCA mutation. These features can be easily and routinely collected at the time of 
diagnosis in conjunction with family history data. Southey, et al., (2011) have shown that 
even in the absence of a supportive family history of breast cancer, the combination of two 
tumour morphological markers, namely, a trabecular growth pattern and a high mitotic index, 
were strong indicators of a BRCA mutation. It seems essential that these markers as well as 
others be evaluated within the black population to reveal whether or not they have significant 
predictive value especially in the absence of a family history of breast and/or ovarian cancer.   
4.3.2 Comparison of Maternal and Paternal Family Histories 
An additional family structure observation is the bias of maternal family history over paternal 
family history. As mentioned previously, 80% of affected relatives were related to the 
proband on her maternal side. Even in probands who had no family history, a significant 
number of individuals reported not having any information relating to paternal history. This 
was an unexpected finding since other studies have suggested no bias towards maternal 
history even in the framework of a female-dominated condition such as breast cancer 
(Hughes, et al., 2003).  
One possible explanation for the lack of paternal family history data in this cohort is the 
observation that many of these women were raised in single parent (usually the mother) 
families and not in the same household as their fathers.  As a consequence they knew very 
little information about their paternal family history. As a result, paternal family history may 
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have been under-ascertained in this cohort. This may impact on the overall family history 
results to a small degree. 
4.3.3 Third Degree Relatives 
The mean number of TDR’s per family (1.20 ± 2.61) was significantly decreased in 
comparison with FDR’s (2.80 ± 1.69) and SDR’s (4.89 ± 2.85). It is possible that this is a 
result of a recall bias or lack of knowledge on the part of the probands or alternatively a lack 
of thorough questioning about more distant relatives by the genetic counsellors. It does not 
seem feasible that this should be taken as a true reflection of the structure of the families 
within this cohort.  
4.3.4 Other Cancers in the Family 
Six female relatives of the probands were reported as having been diagnosed with “womb” 
cancer. The probands were unaware whether or not this diagnosis was indeed uterine 
cancer or alternatively, related cancers such as cervical or ovarian cancers. This would be 
an important distinction to make since uterine and cervical cancers are commonly occurring 
sporadic cancers. In addition, uterine cancer is also known to be associated with HNPCC. 
On the other hand, ovarian cancer is known to be associated with mutations in the BRCA 
genes, especially BRCA1, and would have been supportive of an increased risk of HBOC in 
these families.  
In fact, ovarian cancer is a particularly useful factor in risk assessment for BRCA mutations, 
perhaps even more so than breast cancer. This is evidenced in the Manchester scoring 
system, which assigns a score of 8 for the presence of ovarian cancer diagnosed at less 
than 60 years of age (BRCA1) while the highest score possible for a breast cancer is 6 
(BRCA1), for an individual who is less than 30 years old (Appendix 4).  
Considering the well known association between breast and ovarian cancer in the context of 
inherited breast cancer, it is interesting to note the absence of any reported cases of 
confirmed ovarian cancer diagnoses in the probands or their female relatives. Whether or 
not this implies a lesser role of BRCA mutations in this population as compared to others 
remains to be determined.      
Eight relatives of the probands were reported to have throat cancer. All except one of these 
individuals were males and six of the eight had a confirmed history of smoking. It is 
reasonable to suggest that at least some of these cancers may have been oesophageal 
cancer. This diagnosis would be more in keeping with the high incidence (22.3 per 100 000) 
of oesophageal cancer, particularly in males, in Southern Africa (Farlay, Shin, Bray, et al., 
2010).  
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4.3.5 At-risk Female Relatives 
As outlined previously, 400 female relatives were deemed to be at an increased risk of 
developing breast cancer in their lifetime based on their blood relationship to an individual 
diagnosed with premenopausal breast cancer. This might be an over-estimation of the 
number of individuals at an increased risk. One reason for this over-estimation is that in fact 
an inherited predisposition would only come from one or the other side of the family (for 
autosomal dominant patterns of inheritance) whereas these at-risk relatives were counted 
from both sides of a proband’s family.  
“At-risk” status can only truly be clarified however, once molecular genetic analysis has been 
performed. The knowledge of the presence or absence of a BRCA (or other) mutation in a 
family is essential to delineate further which individuals are truly at an increased risk. This 
knowledge will also be useful in determining individualised screening and prevention 
protocols for truly at-risk relatives (Southey, et al., 2011). 
4.3.6 Comparison of At-risk and Affected Relatives 
In order to gain some insight as to whether or not family history is a useful tool in 
determining breast cancer risk in this population, the ratio of affected and at-risk relatives 
were calculated within each degree of relation. The figures that resulted for FDR’s and 
SDR’s were slightly raised yet comparable with the reported incidence of breast cancer in 
the black South African population (1 in 55). This slight increase may give some suggestion 
of the cohort being at an increased risk. The TDR ratio was hampered by the ascertainment 
bias discussed in section 4.3.3 above.  
This comparison is limited by the fact that the data used to calculate the incidence of breast 
cancer in the local population is histologically based whereas the ratios of affected to at-risk 
relatives are based on family history data. An additional limitation is that this information was 
gathered at only a single point in time. There is reason to believe that other individuals in 
these families could still develop breast cancer at some future point in time. If one was to 
assume an autosomal dominant pattern of inheritance of breast cancer in these families, 
then one would expect to see a rate of approximately 20-30% of breast cancer diagnoses on 
one side of a family (taking into consideration a penetrance of 60%). The fact that these 
ratios were closer to the population risk seems to indicate a trend that there may be a lesser 
degree of genetic predisposition in this population.  
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4.4 Risk Assessment 
Existing breast cancer risk assessment tools were analysed for utilisation and consistency 
within the cohort. Numerous advantages and disadvantages were identified within each of 
the various tools. These are outlined below. The main disadvantage of the use of all of these 
risk assessment tools is that they were designed for use in Caucasian populations and their 
use in non-Caucasian populations is therefore not validated. Ultimately, these individuals 
require detailed mutation screening and analysis in order to determine which, if any, risk 
assessment tool is truly useful to calculate risk in this population.  
In general, results indicated that all of the risk assessment tools that were used did give an 
indication of an elevated risk. This result was more commonly due to a young age at 
diagnosis rather than a striking family history. The risk assessment programmes did not 
show a highly significant degree of consistency among the probands and their families. 
These findings highlight the necessity for the development of a risk assessment tool unique 
to this population.  
4.4.1 Baseline Family History Risk Assessment  
The baseline risk assessment table was used to categorise families into average, moderate 
and high risk for a cancer syndrome based on age at diagnosis of the proband as well as 
family history (Lee, et al., 2005). The table was most frequently used to place families in a 
particular category based on the age of onset of breast cancer in the proband. Only in one 
instance did the family history of an individual modify their placement in a particular risk 
category. As such, the finding that no families were placed at average risk is not surprising. 
As mentioned above, the selection criteria for this study had an innate bias towards young 
breast cancer diagnoses (less than 50 years).  
Upon closer inspection of the 30 families who were placed at high risk according to this 
table, only 3 probands were found to have been diagnosed with breast cancer over the age 
of 40 years and had a positive family history. The significance of their placement in this 
category as well as the utility of this tool can only be confirmed once molecular genetic 
analysis has been performed. However, it seems that this tool is useful for an initial 
delineation of risk. In addition, the table is simple enough to be utilised in the genetic 
counselling session when family history is first obtained and can be easily adapted to the 
circumstances of a particular proband.  
The guidelines given in this table were not particularly stringent however and therefore a 
large quantity of people might be placed at high risk unrealistically. This may in turn lead to 
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over-screening and over-testing which is expensive, time-consuming, and potentially 
unnecessary and may cause increased anxiety.  
4.4.2 Claus Model  
The Claus Model appeared to stratify the hypothetical 20 year old FDRs of the probands 
more thoroughly than the baseline risk assessment, with individuals being placed in all three 
risk categories. Only 2 individuals (4%) were considered to be at high risk (Figure 3-7); 
significantly less than the 30 families who were placed in this category using the previous 
tool.  
The Claus model was designed to be used in the absence of an obvious autosomal 
dominant pattern in a family pedigree (Rubinstein, et al., 2002). It therefore proved to be 
most useful and simple to use when there was no family history aside from the affected 
proband. The Claus tables were not helpful in many of the instances when there was some 
kind of family history. For example, no appropriate table existed for hypothetical FDR’s who 
had three affected relatives. Although the tables are easy to use, they are restricting in terms 
of which families can be analysed. In contrast to the previous tool, they are too stringent and 
inflexible.    
4.4.3 Tyrer-Cuzick Model  
The Tyrer-Cuzick software programme gave information regarding lifetime as well as BRCA 
mutation risks. Only eight of the 45 hypothetical 20 year-old FDRs were given a lifetime risk 
assessment of greater than 20% by the Tyrer-Cuzick model. In fact, all except one of the 20 
year-old FDRs were categorised as moderate risk (Figure 3-7) by this tool (refer to Table 2-
3). In addition, the BRCA scores that were calculated for the families of the probands by this 
software were uniformly low (Figure 3-6).  
These results seem to indicate that this software programme places a large amount of 
emphasis on family history and also takes into consideration unaffected female relatives. 
This is in contrast to the previous tools which placed more emphasis on a proband’s age at 
breast cancer diagnosis in order to calculate risks. The software tool was limited in its ability 
to be manipulated to fit alternative scenarios within the family histories (e.g. TDRs and male 
breast cancers). It seems overall, that the Tyrer-Cuzick software was designed for and is 
most useful for predictive risk calculations rather than for women who have already been 
diagnosed with breast cancer. This is not particularly useful in the setting of the Breast and 
Plastic Clinic, CHB, since all of the women seen at this clinic have already been diagnosed 
with breast cancer but it can be very useful for their relatives. 
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4.4.4 Manchester Scoring System  
The Manchester scoring system also gave consistently low BRCA mutation scores for the 
families of affected probands. This is not surprising since the score places emphasis on 
family history and requires counting of all individuals. It is also weighted according to age at 
cancer diagnoses. The Manchester score also had the added benefit of being able to include 
histological features of a proband’s breast cancer. This had a marked effect on the overall 
scores, especially on the BRCA1 scores. It is interesting to note that only three out of 45 
families would have been offered molecular genetic testing based on their Manchester Score 
result (>20 points) using a threshold of 20%. Only an additional two families would be 
offered testing had the threshold been lowered to 10% (equivalent to 16 points).  
The Manchester scoring system appears to perform better at stratifying probands and their 
families into the various risk categories. This, in addition to its ease of use in the clinical 
context, makes it a good candidate for use within this population as an interim solution for 
risk clarification.   
4.4.5 Comparison of Risk Assessment Models 
In order to verify the consistency of these models in terms of their risk predictions for this 
cohort, it was necessary to convert the data outputs into categorical data of the nature: 
average; moderate and high risk. This manipulation was useful in that it allowed for the 
visualisation of how the different tools stratified the probands and their families.  
As can be seen in Figure 3-7, the baseline assessment placed thirty families at high risk for 
an inherited cancer syndrome. The other three tools all showed a markedly decreased 
amount of individuals and families at high risk (range: 1-3). A much more significant number 
of people were classified in average or moderate risk categories by these tools. This re-
enforces two important findings of this study: 
 Family history may be a significant predictor of risk in this population.  
 The potential contribution of BRCA mutations in a cohort selected on the basis of age 
proportionately might be less than expected when compared to other populations 
because of the large number of young people in the population. 
4.4.5.1 Comparisons between Models 
Both the Claus model and the Tyrer-Cuzick model gave an output of lifetime risk for 
developing breast cancer. They were found to have a strong positive correlation.  The data 
appeared to cluster in the moderate risk category with very few individuals at high risk. It is 
not known how this information relates to these individuals’ true risks. 
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The Manchester scoring system was also compared to the Tyrer-Cuzick model since both of 
these tools gave a risk of identifying a BRCA mutation. In this instance, the correlation was 
positive however not as strong as between the Claus and Tyrer-Cuzick models. There was 
clustering on the average to moderate risk end of the curve, with decreasing correlation as 
the curve approaches high risk. It is possible to surmise from this that the Manchester and 
the Tyrer-Cuzick models are correlated more strongly at lower risk estimates but diverge at 
higher risks.    
4.4.5.2 Comparison of All Models 
The conversion of all risk outputs to a single format highlighted the fact that most probands 
had inconsistent risk outputs. These probands tended to have only one or two of the classic 
features of an inherited cancer syndrome rather than portraying a classic high risk scenario. 
This information highlights the fact that these risk assessment tools were developed for a 
very particular subset of individuals of the broader breast cancer population. In general the 
cohort that was investigated in this study does not conform to these criteria.  
Only a single proband and her family were placed in the same risk category by all of the risk 
assessment tools excluding the Claus Model, which could not be utilised for lack of an 
appropriate table. This was an interesting observation and necessitated a closer examination 
of this individual’s breast disease profile and family history pedigree. This information can be 
visualised in Figure 4-3C.  
The pedigree illustrates that the proband was diagnosed with stage IIB unilateral ductal 
carcinoma at the age of 39 years. In addition, she was found to be negative for expression of 
the oestrogen and progesterone hormone receptors as well as the Her2/neu receptor. 
Further, she had two relatives who had been diagnosed with and died from breast cancer; 
one at a significantly young age (27 years). The combination of these factors (all known to 
confer increased risk for breast cancer) was sufficient to place her in a high risk category 
irrespective of which risk assessment tool was utilised. Interestingly, this family also 
conforms to criteria for Li Fraumeni syndrome and would be eligible for p53 mutation testing. 
In the case of this family, the relevant criteria are: A proband with a Li Fraumeni spectrum 
tumour (premenopausal breast cancer) AND at least one first- or second- degree relative 
with a Li Fraumeni spectrum tumour (mother with leukaemia) before the age of 56 years 
(Tinat, et al., 2009).   
This information, in conjunction with the ANOVA evaluation, emphasizes the idea that young 
black South African women with breast cancer may not necessarily be consistent with the 
expected picture of inherited breast cancer as seen in other population groups and the 
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application of these risk assessment models in this population may not be effective. It also 
re-affirms the necessity for the development of a risk assessment programme designed 
specifically for this cohort and the broader population that it represents.  
The results of the ANOVA analysis emphasized the inconsistency among the various risk 
assessment models. This is not necessarily a surprising finding and to some degree, the 
inconsistency can be ascribed to the design of the individual programmes. Each tool 
considered a unique set of risk factors and parameters in order to produce an output. In 
addition, the tools measured different outputs (lifetime or mutation risks). Based on these 
intrinsic differences in the programme designs, it is possible to postulate that some of this 
inconsistency and variability would be evident in a similarly affected Caucasian population. 
These results seem to suggest one of two options for the future of risk assessment and 
prediction in this population. Either, it will be necessary to use a combination of these tools 
to calculate an accurate risk, or alternatively, develop a new consolidated, risk assessment 
tool that is inclusive of all the potential risk factors and specific for the variation in this 
population. Ultimately, BRCA (or other genetic) mutation testing is the only way in which it 
will be possible to determine which risk assessment (existing or future) will represent risk in 
this population more accurately.   
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5 CONCLUSIONS 
This was a unique study and the first to have examined family history in the context of black 
South African women diagnosed with breast cancer. The study has shown that the black 
South African women examined in this study who have been diagnosed with breast cancer 
at a young age tend to have significant family histories of breast and/or ovarian cancer less 
frequently than would be expected from a high risk cohort selected based on age of 
diagnosis. In addition, existing risk assessment models that are used to predict lifetime and 
mutation risks for breast cancer in other populations were found to give increased risks of 
breast cancer when diagnoses are made at younger ages and there is a family history. 
However, the use of these models within this population should be done with caution due to 
the limitations discussed previously. The main findings and limitations of this study are re-
iterated below. Recommendations for genetic counselling practices and future research are 
also expounded.   
5.1 Summary of Study Findings 
The major findings of this study need to be viewed as theoretical since no BRCA (or other) 
mutation analysis has been performed as yet. The findings are summarised as follows: 
 Evidence seems to suggest that the age distribution of breast cancer in this 
population may be in part, as a consequence of the population structure rather than 
an increased incidence of HBOC in this population. In other words, the fact that many 
women were diagnosed with breast cancer at young ages may be reflective of the 
fact that the median age of this population is shifted significantly towards the left and 
these women might in fact have sporadic breast cancers as opposed to inherited 
breast cancers.  This is in agreement with previous studies that have shown a trend 
towards younger age at diagnosis in African populations (Walker, et al., 2004; 
Uhrhammer, et al., 2008;)  
 Overall, the specifics of breast cancer in this cohort of black South African women 
appeared to parallel those of breast cancer in other African populations. That is, 
breast cancers were diagnosed at younger ages and later stages and there was an 
increased incidence of triple negative breast cancer. 
 It is possible that mutations in BRCA genes might not be the only contributors to 
breast cancer predisposition in this population. This necessitates an extensive 
molecular genetics workup in this cohort, including other high penetrance genes (e.g. 
p53 and pTEN) and lower penetrance genes (e.g. PALB2, CHEK2, ATM).   
 The pedigree analysis revealed that there was a paucity of family history related data 
in this cohort. Those four probands and their families, who were found to have a 
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significant family history, are most likely to have an inherited predisposition to breast 
cancer. However, the many other probands who were the only affected member in a 
family are more likely to have sporadic breast cancers irrespective of the young age 
at diagnosis. It seems that this population would benefit from an investigation into 
alternative predictors of breast cancer risk since they do not appear to conform to 
existing strategies of identification. Age at diagnosis, in particular, may be a poor 
predictor of risk. 
 The various risk assessment tools proved to have many different advantages and 
disadvantages with respect to their general usage and specifically with respect to 
their use in this population. There was some degree of consistency among the 
various tools; however they should be used in this population with caution. Risk 
assessment tools should be re-evaluated in this population once genetic testing has 
been performed on these probands. It is likely that a risk assessment tool will need to 
be designed specifically for use in this population. 
 Only once comprehensive genetic screening, perhaps of many genes, has been 
performed, will the epidemiology of breast cancer in black South African women be 
fully interpreted. 
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5.2 Summary of Study Limitations 
The major limitations of this study are outlined below: 
 Even though the cohort appeared to be well matched to the greater population of 
young, urban, black South African women with breast cancer in terms of 
demographics and socioeconomic factors, the sample size was small (N=45). This 
made generalization of the statistical analyses to the population of interest more 
complex.  
 Collection of family history data was impeded for a number of reasons discussed 
above. Family history data collection is a notoriously difficult task to perform 
accurately. In addition an accurate and complete family history is often obtained over 
an extensive period of time with significant effort on the proband’s behalf. This is not 
feasible in a busy clinical setting especially when dealing with young women who 
have recently been diagnosed with breast cancer. Even in the instance of accurate 
information, only an extremely obvious family history would be useful as a predictive 
tool for breast cancer risk.  
 The risk assessment programmes utilized in this study were all designed on the basis 
of Caucasian breast cancer data. Consequently, their applicability and utility in a non-
Caucasian population remains to be verified. 
 The lack of mutation data specific to this population makes all risk data presented in 
this study unverifiable at present.      
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5.3 Study Recommendations 
A number of recommendations can be made based on the findings of the present study.  
5.3.1 Recommendations for identifying black South African women at increased 
risk for a familial breast cancer syndrome 
 
 Women who have been identified as being at elevated risk for HBOC are most likely 
to benefit from specifically designed management and screening programmes, which 
include genetic counselling. These strategies are well defined for breast cancer 
prevention and less so for ovarian cancer. There is reasonable evidence to suggest 
that a combination of these strategies can impact on the occurrence as well as 
morbidity and mortality of breast and/or ovarian cancer in many populations (Hughes, 
et al., 2003). Strategies should include the encouragement of self- and clinical- 
breast examinations as well as mammography at appropriate ages. It is therefore 
prudent to suggest that such strategies be implemented and reinforced in the black 
South African population even in the absence of concrete proof of a genetic 
contribution to breast cancer in this population and in the presence of a limited 
resource environment.  
 In order to establish such strategies effectively, it is essential that the process of 
identifying women at high risk in the black South African population be adapted to 
best suit these women. An appropriate screening protocol for identifying women who 
require a more intensive screening and management programme could be proposed 
based on the results of this study. Figure 5-1 suggests an interim risk assessment 
tool.   
 It is essential to bear in mind that the strategy put forward here needs to be seen as 
an interim solution and would need to be re-evaluated pending the completion of 
molecular genetic analysis in this population. As a consequence of this, it would be 
important that the criteria used to identify at-risk women be kept flexible rather than 
stringent at present. A potentially damaging drawback of this is that women who are 
not truly at high risk might be identified. The anxiety level of such a woman might be 
unnecessarily raised.      
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Figure 5-1 Interim breast cancer risk assessment guidelines for black South African women 
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5.3.2 Recommendations for Future Research: 
 
 Considering the results of this study suggest that there may be a potentially smaller 
role for inherited breast cancer in this population, it seems vital that molecular genetic 
analysis of other familial cancer related genes (e.g. p53, pTEN, PALB2, CHEK2, 
ATM) be undertaken in addition to the imminent BRCA gene analysis in order to 
ensure the full spectrum of potentially contributing genes are evaluated within this 
population. 
 It seems that an important step in the delineation of HBOC in this population would 
be to investigate whether or not any family history of cancer exists for black South 
African women who have been diagnosed with ovarian cancer. Since ovarian cancer 
is a significant predictor of HBOC, such a study would help to confirm the results of 
the present research as well as inform the overall picture of HBOC in the local 
context.   
 It also seems important to suggest that the research performed in this study be 
expanded to include a larger cohort of affected black South African women of all 
ages and from other parts of Gauteng specifically and South Africa in general. In this 
way, the findings presented here may be corroborated or refuted and it will be 
possible to gain a greater understanding of the scope of inherited breast cancer in 
the black South African population.  
 
5.3.3 Recommendations Regarding the Genetic Counselling Service for Inherited 
Breast Cancer: 
 
 It has been noted that there is an increase in interest (from patients and staff) in, as 
well as referrals to the genetic counselling service at the Breast and Plastic Clinic, 
CHB. This, in conjunction with the indication that inherited breast cancer is very likely 
to be present in the black South African population (albeit to a lesser extent), 
indicates that the genetic counselling service should remain functional at this clinic. 
Appropriately triaged new patients as well as their families should be offered genetic 
counselling as part of routine breast cancer management.  
 Following from this, it would be essential to take an active approach in educating 
medical professionals about inherited breast cancer in general as well as the 
appropriate referrals within this population to genetic counselling specifically. This 
could be achieved through workshops, seminars and presentations to those doctors 
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involved in treating affected individuals within this population. The importance of 
family history taking should be emphasized to these professionals. Nurses involved 
with the treatment of individuals with breast cancer should also be encouraged to 
make appropriate referrals to genetic counselling.    
 Individuals previously seen for genetic counselling in the breast cancer context 
should be given follow-up appointments regularly to monitor their progression as well 
as maintain up-to-date information regarding other affected family members and at-
risk individuals. It is essential that at-risk individuals be provided with information 
regarding their risks (perhaps in the form of an information leaflet) as well as their 
options regarding genetic counselling, surveillance and testing (including contact 
information). A data management system would be essential to maintain the 
information of patients seen as well as their relatives and allow for prompt 
identification of at-risk individuals.  
 It has become apparent that the breast cancer patients being seen at the Genetic 
Counselling Clinic would find it beneficial to have additional non-medical support 
systems in place. For example, there is potential for the Genetic Counselling Clinic to 
play a role in initiating and maintaining a patient-run support group at the Breast and 
Plastic Clinic, CHB.  
 
The above summary indicates that this study has contributed to the current understanding of 
family history and inheritance of breast cancer in black South African women. Further, this 
study has been instrumental in providing a framework and direction for future research with 
respect to the genetics of breast cancer in this population as well as informing genetic 
counselling practice in the context of HBOC or other cancer predisposition syndromes. This 
study also highlights the importance of genetic counselling services within routine breast 
cancer management, which will improve with increasing knowledge.  
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7.2 Appendix 2 - Information Sheet and Informed Consent Form 
 
 
 
 
 
Information Sheet: Family History and Risk Assessment in Black South African Women with Breast Cancer 
Investigator: Tasha Wainstein, MSc (Med) Genetic Counselling Student 
Good day, my name is Tasha Wainstein. I am a student in the Division of Human Genetics, National Health Laboratory Service (NHLS) 
and the University of the Witwatersrand (Wits).  
As part of my studies, I will be conducting research to try to understand why African women develop breast cancer. Breast cancer affects 
many women worldwide. In South Africa, approximately 1 in 50 black women will develop breast cancer in their lifetime. At present, little is 
known about the way in which breast cancer occurs within black South African families. Although most forms of breast cancer occur by 
chance, some cases can be inherited from one generation to the next. My study therefore aims to identify whether or not there is a 
significant family history in black women who have breast cancer. I will be using risk assessment programmes to predict the theoretical 
risks for you and your family members of developing breast cancer in your lifetimes or of having a gene that may cause breast cancer. In 
the future, those individuals who are found to be at an increased risk may then be able to participate in various cancer prevention 
strategies and genetic testing research. 
I would like to invite you to participate in this study by allowing me to use your family history information and assess your personal breast 
disease history in my analysis by analysing your genetic counselling file in more detail after your routine genetic consultation. 
This information will be gathered and discussed in detail in a routine genetic consultation that will take place at the Breast and Plastic 
Clinic at the Chris Hani Baragwanath Hospital. This consultation will take approximately one hour. During the genetic consultation, you will 
be asked numerous questions about your family history and this information will be used to construct a family pedigree. Information such 
as the names, ages, and possible diagnoses of your children, siblings, parents and other relatives will be sought. We will also discuss 
aspects of your personal breast cancer history and treatment. Following this, we will discuss current knowledge of the genetics of breast 
cancer as well as important information regarding screening and management for yourself and your family members. I will use the family 
pedigree drawn in the session and the personal breast disease history that you or your doctor has provided in my analysis.  
This project will help us to understand more about inherited breast cancer in the black population. This study might not help you directly. It 
will not make you better. Your treatment will continue just as before. This may help your family as well as other families in the future. 
Your participation in this study is voluntary. You have the right to refuse to participate in the study. Also, you have the right to withdraw 
from the study at any time. Your refusal or withdrawal will not affect present or future treatments. This would not exclude you from being 
offered genetic counselling, which is part of the routine service we offer at the Breast and Plastic Clinic.  
All your personal information will be kept strictly confidential and data obtained from the study will be anonymised.  
If you have any questions about your participation, please do not hesitate to contact me or my colleagues on the numbers listed below.  
Thank you, 
Ms. Tasha Wainstein - BSc (Hons) Human Genetics, Genetic Counselling Student - 011-489-9223/4 
Prof Amanda Krause - MBBCh, PhD, Associate Professor and Head of Clinical Section - 011-489-9219  
Ms. Chantel van Wyk - MSc (Med) Genetic Counselling, Genetic Counsellor - 011-489-9236 
If you have any queries, complaints or problems regarding this information please contact the Chairman of the Research Ethics 
Committee, Professor Peter Cleaton-Jones, on 011 717 1234. 
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Consent Form 
Family History and Risk Assessment in Black South African Women with Breast Cancer 
 
I, _________________________________________________, certify that: 
1. The research has been explained to me and I understand that my family history and personal breast 
disease history will be analysed. 
2. The information collected about me will be kept confidential. 
3. I understand why the study is being done and that it may have benefits for me/my child/my extended 
family. The study will help researchers to understand inherited breast cancer so that they may develop 
ways to prevent inherited breast cancer in the future. 
4. I have had sufficient opportunity to ask questions about the research and I have decided to participate in 
the study without coercion. 
5. I understand that I do not have to participate in this study. If I choose not to participate, it will not affect 
the way I am treated at the hospital/clinic. Similarly, if I choose to withdraw from the study at any time, it 
will not affect any future treatment I may require. 
My decision for the use of my information once the study is completed is (please mark with an X): 
 If possible, my information should be stored for future analysis in my interest (on my request). 
 My information may be used for medical research: 
 With my name, 
 Without my name (anonymous). This means that I cannot be informed about eventual results. 
 My information must be discarded once the study is completed. 
 I would like to be notified of results of the study 
 I give permission for the researcher to view my clinical notes. 
 I give permission for the researcher to receive copies of my histology reports and scans. 
 
Signed on this ________ day of __________ 20______ at ___________________________________________ 
Patient 
Name: _________________________  Signature: ___________________________ 
Witness 
Name: _________________________  Signature: ___________________________ 
Researcher: 
Name: ________________________  Signature: ___________________________ 
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7.3 Appendix 3 - Data Collection Sheets 
1. General Information 
       
Subject Code:     
       
Related to other family file code:     
       
Date of Birth: dd mm yyyy   
       
Age: current   at diagnosis     
       
Gender: male   female     
       
Ethnicity / Tribal Origin: IsiNdebele   IsiXhosa   IsiZulu   
       
 Sepedi   Sesotho   Setswana   
       
 siSwati   Tshivenda   Xitsonga   
       
Description of Counsellee(s): 
Breast Cancer 
<50 years 
  
Breast Cancer >50 
years + family history 
    
       
Description of Support Person/s 
parent of 
proband 
  child of proband     
       
 
sibling of 
proband 
  non-relative     
       
Occupation Status: employed   unemployed   previously employed   
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2. Family History Data 
           
Pedigree drawing including necessary information* for healthy and affected children, siblings, parents, aunts, 
uncles, cousins and grandparents: 
*"Necessary Information" includes:  age; date of death; age at diagnosis; type of cancer; cause of death 
           
                      
             
             
             
             
             
             
             
             
             
             
                      
           
Number of affected 1st degree relatives    Number of unaffected 1st degree relatives   
Number of affected 2nd degree relatives    Number of unaffected 2nd degree relatives   
Total number of affected relatives    Total number of unaffected relatives   
           
Number of 1st degree at-risk female relatives**         
Number of 2nd degree at-risk relatives         
Total number of at-risk relatives         
           
** "at-risk female relatives" have an increased risk of developing breast cancer in their lifetime and include 
relatives from the proband's generation and below as well as from the proband's parents' generation 
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3. Proband Breast Disease History 
        
Precancerous Breast Conditions: 
Atypical Ductal Hyperplasia    Ductal Carcinoma In Situ    Lobular Carcinoma In Situ   
        
Breast Cancer Type: 
Ductal    Lobular    Other*   
        
Breast Cancer Laterality:  
Unilateral    Bilateral      
        
Tumour Staging*: 
Tumour Size    Node Involvement    Metastasis   
        
Histology*: 
Oestrogen Receptor Status    
Progesterone Receptor 
Status 
   Her2 Receptor Status   
        
Other Cancers: 
Ovarian    Cervical    Uterine   
Thyroid    Melanoma    Other*   
        
Hormonal Factors*: 
Age at 1st Period    Age at 1st Pregnancy    
Duration of Contraception 
Use 
  
Duration of Breast Feeding (for all 
children) 
   Age at Menopause    Duration of HRT Use   
        
Surgery: 
Lumpectomy    Therapuetic Mastectomy    Prophylactic Mastectomy   
Hysterectomy    Oophorectomy      
        
*Specify        
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4. Risk Assessment Data 
        
Risk of Having an inherited cancer syndrome in the family* 
        
*Based on family history data alone (refer to Table 1, page 4 of Research Proposal) 
        
Average     Moderate    High   
Claus Output** 
        
         
        
Tyrer-Cuzick Output** 
        
10 year risk prediction output    beyond 10 year risk prediction ouput    mutation risk output   
        
Manchester Score** 
        
BRCA1 Score    BRCA2 Score    Combined Score   
        
** Risk calculated for a twenty-year old first-degree female relative of the affected individual 
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7.4 Appendix 4 - Frequently Used Claus Tables 
7.4.1 Claus Table 1 
 
7.4.2 Claus Table 2  
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7.4.3 Claus Table 4 
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7.5 Appendix 5 - Manchester Scoring System 
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